US20050186211A1 - Use of mda-5 as an antiviral and antiproliferative agent - Google Patents
Use of mda-5 as an antiviral and antiproliferative agent Download PDFInfo
- Publication number
- US20050186211A1 US20050186211A1 US11/042,922 US4292205A US2005186211A1 US 20050186211 A1 US20050186211 A1 US 20050186211A1 US 4292205 A US4292205 A US 4292205A US 2005186211 A1 US2005186211 A1 US 2005186211A1
- Authority
- US
- United States
- Prior art keywords
- mda
- protein
- ifn
- agent
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000840 anti-viral effect Effects 0.000 title description 7
- 230000001028 anti-proliverative effect Effects 0.000 title description 3
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims abstract description 148
- 101710085994 Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims abstract description 146
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 230000000694 effects Effects 0.000 claims abstract description 77
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 108091006112 ATPases Proteins 0.000 claims abstract description 51
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims abstract description 51
- 230000009385 viral infection Effects 0.000 claims abstract description 22
- 208000036142 Viral infection Diseases 0.000 claims abstract description 20
- 230000015556 catabolic process Effects 0.000 claims abstract description 14
- 238000006731 degradation reaction Methods 0.000 claims abstract description 14
- 230000000670 limiting effect Effects 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 241000700605 Viruses Species 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 45
- 108060004795 Methyltransferase Proteins 0.000 claims description 38
- 102000014150 Interferons Human genes 0.000 claims description 11
- 108010050904 Interferons Proteins 0.000 claims description 11
- 230000004952 protein activity Effects 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 229940079322 interferon Drugs 0.000 claims description 9
- 230000002301 combined effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 abstract description 42
- 102000039446 nucleic acids Human genes 0.000 abstract description 39
- 108020004707 nucleic acids Proteins 0.000 abstract description 39
- 102000004409 RNA Helicases Human genes 0.000 abstract description 27
- 108090000944 RNA Helicases Proteins 0.000 abstract description 25
- 230000006907 apoptotic process Effects 0.000 abstract description 15
- 230000004663 cell proliferation Effects 0.000 abstract description 10
- 230000002950 deficient Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000006882 induction of apoptosis Effects 0.000 abstract description 4
- 230000005860 defense response to virus Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 126
- 108090000467 Interferon-beta Proteins 0.000 description 53
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 49
- 102100026720 Interferon beta Human genes 0.000 description 49
- 230000014509 gene expression Effects 0.000 description 48
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 39
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 39
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 32
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 32
- 238000011282 treatment Methods 0.000 description 30
- 230000004069 differentiation Effects 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 24
- 230000006698 induction Effects 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 20
- 201000001441 melanoma Diseases 0.000 description 16
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 15
- 102000021350 Caspase recruitment domains Human genes 0.000 description 14
- 108091011189 Caspase recruitment domains Proteins 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 8
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 8
- 238000000636 Northern blotting Methods 0.000 description 8
- 102000003923 Protein Kinase C Human genes 0.000 description 8
- 108090000315 Protein Kinase C Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000011712 cell development Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- 102000006992 Interferon-alpha Human genes 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000000411 inducer Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 101000952095 Sus scrofa Antiviral innate immune response receptor RIG-I Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 5
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 5
- 241000711549 Hepacivirus C Species 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000001613 nuclear run-on assay Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 4
- 206010053759 Growth retardation Diseases 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000702244 Orthoreovirus Species 0.000 description 4
- 108010057163 Ribonuclease III Proteins 0.000 description 4
- 102000003661 Ribonuclease III Human genes 0.000 description 4
- 241000710961 Semliki Forest virus Species 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000030570 cellular localization Effects 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 230000003061 melanogenesis Effects 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000710929 Alphavirus Species 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101710151743 Eukaryotic translation initiation factor 2 subunit 1 Proteins 0.000 description 3
- 102100035549 Eukaryotic translation initiation factor 2 subunit 1 Human genes 0.000 description 3
- 101710164432 Eukaryotic translation initiation factor 2 subunit alpha Proteins 0.000 description 3
- 206010061192 Haemorrhagic fever Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010023927 Lassa fever Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 101710130520 Translation initiation factor 2 subunit alpha Proteins 0.000 description 3
- 230000005756 apoptotic signaling Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000005014 ectopic expression Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960001388 interferon-beta Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- -1 or phage Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 2
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 2
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 2
- 241000617996 Human rotavirus Species 0.000 description 2
- 101150103227 IFN gene Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
- 101710165374 Putative helicase Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108010049219 RNA-dependent ATPase Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000007711 cytoplasmic localization Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 102000003898 interleukin-24 Human genes 0.000 description 2
- 108090000237 interleukin-24 Proteins 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 108030002617 2'-5' oligoadenylate synthases Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007407 African swine fever Diseases 0.000 description 1
- 241000702419 Ambidensovirus Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000702652 Aquareovirus Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241001533426 Avibirnavirus Species 0.000 description 1
- 241000701397 Avihepadnavirus Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000724653 Borna disease virus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000002164 CARD domains Human genes 0.000 description 1
- 108050009503 CARD domains Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102100029226 Cancer-related nucleoside-triphosphatase Human genes 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 238000002883 ClustalW sequence alignment Methods 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 241000702669 Coltivirus Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000702662 Cypovirus Species 0.000 description 1
- 241000712467 Cytorhabdovirus Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 101100232687 Drosophila melanogaster eIF4A gene Proteins 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 206010014614 Encephalitis western equine Diseases 0.000 description 1
- 241001533423 Entomobirnavirus Species 0.000 description 1
- 241001455610 Ephemerovirus Species 0.000 description 1
- 241000121268 Erythroparvovirus Species 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000702658 Fijivirus Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001037191 Homo sapiens Hyaluronan synthase 1 Proteins 0.000 description 1
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101001052435 Homo sapiens Ubiquitin carboxyl-terminal hydrolase MINDY-3 Proteins 0.000 description 1
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102100040203 Hyaluronan synthase 1 Human genes 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- 241000121270 Iteradensovirus Species 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000701043 Lymphocryptovirus Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001302042 Methanothermobacter thermautotrophicus Species 0.000 description 1
- 241000700559 Molluscipoxvirus Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000701034 Muromegalovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 241000712466 Nucleorhabdovirus Species 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000700732 Orthohepadnavirus Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000712894 Orthotospovirus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000702656 Phytoreovirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000701037 Rhadinovirus Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000122129 Roseolovirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100024205 Ubiquitin carboxyl-terminal hydrolase MINDY-3 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000701067 Varicellovirus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 241000710951 Western equine encephalitis virus Species 0.000 description 1
- 241000700574 Yatapoxvirus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 229940088900 crixivan Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940072253 epivir Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000005098 feline infectious peritonitis Diseases 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229940108452 foscavir Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 239000003084 hiv integrase inhibitor Substances 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000050338 human USP18 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000010661 induction of programmed cell death Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000011542 interferon-beta production Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000018901 negative regulation of programmed cell death Effects 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical class CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000700570 unidentified entomopoxvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present invention relates to melanoma differentiation associated gene-5 (mda-5) nucleic acids, MDA-5 proteins, and the mda-5 gene promoter and related molecules, and the use of these elements to protect against or limit viral infection, to control cell proliferation and to induce apoptotic cell death. It is based, at least in part, on the discovery that MDA-5 protein exhibits ATPase activity.
- Terminal differentiation is essential for normal development and homeostasis (Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-56).
- this process can go awry in cancer cells, resulting in uncontrolled proliferation and an inability to respond to normal growth-inhibitory signals (Fisher et al., 1985, Pharmacol Ther 27(2):143-66; Waxman S., 1995, Differentiation Therapy , Waxman, ed., Sereno Symposium Publications: Rome, Italy. pp. 1-531).
- cancer cells evolve, ultimately developing new phenotypes or acquiring a further elaboration of pre-existing transformation-related properties, the expression of differentiation-associated traits often undergoes a further decline.
- differentiation therapy may prove less toxic than currently employed chemotherapeutic approaches, including radiation and treatment with toxic chemicals.
- the clinical application of differentiation therapy will require the identification of the genes and pathways involved in determining cell fate, as well as the development of appropriate in vitro and in vivo model systems for identifying and characterizing the appropriate agent or agents that can modulate differentiation in cancer cells without causing undue toxicity to normal cells.
- IFN- ⁇ or MEZ When administered alone, IFN- ⁇ or MEZ can induce specific differentiation-associated changes in melanoma cells including growth suppression, melanogenesis, and alterations in morphology.
- these changes in phenotype are fully reversible after removal of the inducer (Fisher et al., 1985, J. Interferon Res 5:11-22; Jiang et al., 1993, Mol Cell Different 1:41-66; Jiang et al., 1994, Mol Cell Different 2:221-239; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-56).
- this differentiation system represents an ideal model to study growth control, differentiation (both reversible and terminal), and tumor suppression.
- cDNA libraries were prepared from temporal RNA samples obtained from HO-1 human melanoma cells treated with IFN- ⁇ +MEZ and control, untreated HO-1 cells and control cDNAs were subtracted away from differentiation inducer-treated cDNAs (Id.). This approach resulted in an enrichment of genes displaying elevated expression as a function of treatment with the different inducers and the induction of irreversible growth suppression and terminal cell differentiation.
- melanoma differentiation associated (mda) genes Four classes of genes, called melanoma differentiation associated (mda) genes, have been cloned using this approach (Jiang and Fisher, 1993, Mol Cell Different 1:285-299). These include genes displaying elevated expression as a function of treatment with: IFN- ⁇ and IFN- ⁇ +MEZ (Type I mda genes); MEZ and IFN- ⁇ 3+MEZ (Type II mda genes); IFN- ⁇ , MEZ and IFN- ⁇ +MEZ (Type III mda genes); and predominantly with IFN- ⁇ +MEZ (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang et al., 1994, Mol Cell Different 2:221-239).
- Phage-based cDNA-subtracted libraries and a rapid subtraction hybridization (RaSH) approach have been used to define the relevant gene changes associated with induction of terminal differentiation (Jiang et al., 1993, Mol Cell Different 1:41-66; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-156).
- Subtraction hybridization between a temporally-spaced differentiation inducer (IFN- ⁇ +MEZ)-treated HO-1 human melanoma cDNA library and a temporally-spaced, untreated control HO-1 cDNA library identified a differentially-expressed 0.3 kb EST, designated melanoma differentiation associated gene-5 (mda-5; Jiang and Fisher, 1993, Mol Cell Different 1:285-299; U.S. Pat. No. 5,643,761 by Fisher et al., filed Oct. 23, 1993 and issued Jul. 1, 1999; International Patent Application No. PCT/US94/12160, publication No. WO 95/11986 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Oct. 24, 1994).
- IFN- ⁇ +MEZ temporally-spaced differentiation inducer
- FIG. 1 A full-length mda-5 cDNA ( FIG. 1 ; SEQ ID NO:1) has now been cloned by using a modified rapid amplification of cDNA ends (RACE) approach (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001).
- the cDNA is 3,365 bp in length, excluding the polyA tail.
- Two ATTTA motifs which are commonly found in RNA species that are rapidly turned over, are present at positions 3,225 and 3,284.
- a poly A signal (AATAAA) is located 23 bp upstream of the poly A tail.
- mda-5p a variant of mda-5, named mda-5p (SEQ ID NO:4), which contains an additional 202 bp attached to the 3′ end of mda-5, was identified by screening a placental cDNA library (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). Since the poly A signal for mda-5p is also located 23 bp upstream of its poly A tail, while the open reading frame (ORF; see below) remains constant, mda-5p is possibly an alternatively poly-adenylated variant of mda-5.
- An ORF is present in the mda-5 cDNA which extends from nt 169 to 3,246, and encodes a predicted protein of 1,025 amino acids having a molecular mass of 116.7 kDa (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001).
- the primary sequence of this predicted protein is shown in FIG. 2 (SEQ ID NO:2).
- SEQ ID NO:2 In vitro translation of the mda-5 cDNA results in a protein with an apparent molecular mass of 120 kDa and additional smaller bands, most likely truncated translation products of MDA-5.
- the mda-5 gene is an early IFN- and tumor necrosis factor- (TNF- )-responsive gene, the transcription of which is increased by treatment with IFN- ⁇ and IFN- ⁇ +MEZ. Thus, this gene may play a significant role in IFN-induced growth suppression and/or apoptosis.
- Identification, cloning and analysis of upstream genomic sequences has identified an mda-5 promoter element ( FIG. 3 ; SEQ ID NO:3) and has confirmed that the mda-5 gene is responsive at the transcriptional level to induction primarily by IFN- ⁇ and dsRNA (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001).
- IFN The cellular responses induced by IFN constitute an organism's primary defense against virus infection. Upon infection, IFN gene expression is induced, IFN-encoding RNA transcripts are translated, and IFN proteins are rapidly secreted from the cell. These IFNs may then exert a variety of effects on surrounding cells, the goal of which is to protect those cells from secondary virus infection.
- IFN molecules may be produced, depending on the type of cell infected.
- type I IFNs IFN- ⁇ and IFN- ⁇ , are released from infected leukocytes and fibroblasts, respectively.
- Type I IFNs interact with specific receptors on the cell surface, activating a signaling cascade pathway that leads to the transcriptional induction of at least 30 genes (Sen et al., 1993, Adv Virus Res 42:57-102). Two of these IFN-induced genes encode the enzymes 2′-5′-oligoadenylate synthase (OAS) and protein kinase R (PKR).
- OFAS 2′-5′-oligoadenylate synthase
- PSR protein kinase R
- Both of these enzymes are activated by the binding of dsRNA molecules, including those present in the cell cytoplasm following the infection of the cell by certain RNA or DNA viruses (see below).
- the activation of OAS by dsRNA increases the synthesis of 2′-5′ oligoadenylates, which in turn activate RNase L.
- RNase L nonspecifically degrades single-stranded RNAs and thus limits the replication of viruses with single-stranded RNA genomes or for which single-stranded RNA molecules are formed as intermediates during replication of the virus genome (Player and Torrence, 1998, Pharmacol Ther 78(2):55-113).
- PKR activation leads to a number of different cellular responses. For example, activation of PKR leads to induction of type I IFN gene expression (Der and Lau, 1995, Proc Natl Acad Sci USA 92(19):8841-8845), creating a positive-feedback loop enhancing the antiviral activities of these molecules. PKR activation also triggers the phosphorylation of several cellular proteins, including the eukaryotic translation initiation factor eIF-2- ⁇ and the inhibitor of nuclear factor-KB (I ⁇ B). Phosphorylation of eIF-2- ⁇ leads to the stabilization of the complex formed between eIF-2- ⁇ and eIF-2B, preventing further translation initiating events.
- I ⁇ B nuclear factor-KB
- PKR activation of PKR by IFN in the presence of dsRNA blocks the further synthesis of both cellular and viral proteins (Pain, 1996, Eur J Biochem 236(3):747-71). Phosphorylation of I ⁇ B results in the activation of NF- ⁇ B (Kumar et al., 1994, Proc Natl Acad Sci USA 91(14):6288-6292), which in turn induces the transcription of a host of genes whose protein products are important regulators of apoptosis, including p53, c-Myc, Fas, FasL, IRF-1 and caspase-1.
- PKR is an important molecule in preventing replication of viral genomes, the synthesis of virus proteins and inducing programmed cell death in virally-infected cells.
- IFNs Although initially recognized as potent antiviral agents, it is now apparent that IFNs also induce other profound cell-type specific effects, including growth inhibition, modulation of differentiation, induction or inhibition of programmed cell death (apoptosis), and regulation of immune system genes and their expression. As introduced above, the growth inhibitory and/or apoptotic effect of type I IFNs are mediated, at least in part, by modulation of RNA translation and degradation.
- RNA helicases may also play important roles in diverse processes of RNA metabolism, including degradation, translation and editing.
- Helicases utilize the energy provided by the hydrolysis of ATP to catalyze the unwinding of nucleic acid duplexes.
- All of the proteins with confirmed helicase activity examined to date contain a number of conserved sequence motifs. These motifs have been used as predictors of helicase activity, leading to the identification of more than two hundred real or putative helicase proteins (Reuven et al., 1995, J Bacteriol 177(19):5393-5400).
- helicases share at least seven motifs encoding various functional or structural domains.
- functional domains include the ATPase A domain, the ATPase B domain, the nucleic acid binding domain, and the helicase domain (for a review, see Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-296).
- Detailed comparisons of these motifs have lead to the classification of helicases into families and superfamilies (Gorbalenya and Koonin, 1993, Curr Opin Struct Biol 3:419-429).
- Superfamily II contains the RNA helicases and can be subdivided into the DEAD, DEAH and DExH families based on their deviating ATPase B domains (Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-96).
- helicase proteins In addition to the seven domains used to classify helicases, some putative or known helicase proteins also contain domains that suggest additional functions, such as RNase III activity. RNase III degrades double-stranded RNA, and has been implicated in gene silencing by RNA interference (Bernstein et al., 2001, Nature 409(6818):363-366). Thus, at least some helicases, through their unwinding of dsRNA, may promote the degradation of single stranded and double stranded RNA molecules.
- Double-stranded polynucleotides have been shown to be present in the replicative cycle of every virus studied to date, regardless of whether its genome is double-stranded or single-stranded, or composed of DNA or RNA (Kadare and Haenni, 1997, J Virol 71(4):2583-90).
- RNA helicases of superfamily II have been identified in the genomes of many viruses, including poxviruses such as vaccinia, alphaviruses such as Semliki Forest virus (SFV), flaviviruses such as hepatitis C virus (HCV), reoviruses such as human rotaviruses A and B, and picornaviruses such as polio virus, among others.
- RNA helicases studied to date exhibit NTPase activity, which is an absolute requirement for RNA unwinding.
- enzyme activity of virus-derived RNA helicases is further stimulated by the presence of RNA, although this feature is not universal.
- viruses with dsRNA genomes there seems to be a correlation between genome size and the presence of an RNA helicase, leading some investigators to conclude that the relative stability of the duplex forms of longer genomes must be disrupted through helicase activity to facilitate replication and translation of the virus genome.
- RNA helicases may function to disrupt intramolecular base-pairing within the RNA genome or to minimize the formation of RNA duplexes during replication of the genome.
- Other potential functions of RNA helicases in the life-cycle of viruses include: 1) mediating the separation of duplexes or regions of secondary structure so that transcription may begin, 2) assisting in proof-reading functions during polymerase function so that fidelity is maintained during replication, and 3) disrupting secondary structures in mRNA so that ribosomal attachment can occur, thereby facilitating the initiation of translation.
- MDA-5 Sequence analysis of the MDA-5 protein revealed a RNA helicase signature domain which spans the C-terminal half of the molecule.
- International Patent Application No. PCT/US01/06960 Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001.
- MDA-5 contains four unique features that could mediate functional divergence from other RNA helicases (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001).
- the CARD domain of MDA-5 in its N-terminal region is not found in any previously identified helicase.
- the ATPase A motif of MDA-5 is unique and contains the region LPTGSGKT as opposed to the sequence found in other RNA helicases (GXXGXGKT).
- International Patent Application No. PCT/US01/06960 suggests that because of this sequence divergence, MDA-5 may not bind ATP effectively, and therefore may be an ATPase defective helicase, or may require a different energy source and/or metals for activity.
- the present invention relates to mda-5 nucleic acids, MDA-5 proteins, the mda-5 promoter, and related molecules, and the use of each of these elements in protecting against or limiting viral infection, controlling cell proliferation, and promoting apoptosis. It is based upon the invention contained in International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, which is incorporated by reference in its entirety herein, and further on the discovery that, contrary to earlier hypotheses based on the amino acid sequence of MDA-5, the protein is not a defective ATPase but rather exhibits ATPase activity. This supports the role of MDA-5 as a RNA helicase protein and consequently its use in promoting RNA degradation, for example in the context of an antiviral defense, limitation of cell proliferation, or induction of apoptosis.
- FIG. 1 mda-5 cDNA sequence (SEQ ID NO:1).
- FIG. 2 MDA-5 protein sequence (SEQ ID NO:2).
- FIG. 3 mda-5 gene promoter sequence (SEQ ID NO:3)
- MDA-5 (SEQ ID NO.:2); Q9HAM6 (SEQ ID NO.:12); RHIV-1 (SEQ ID NO.:13); RIG-1 (SEQ ID NO.:14); P34529 (SEQ ID NO.:15); Q9SP32 (SEQ ID NO.: 16); Q09884 (SEQ ID NO.: 17).
- FIG. 5 (A-D). Expression of mda-5. Northern blot analyses of mda-5 after treatment with melanoma differentiation-inducing reagents (A) and growth factors (B) are shown. HO-1 cells were treated with the indicated reagents for 24 hours.
- concentrations in A are: control (CTL); 0.1% DMSO; 10 ng/ml MEZ; 2,000 units/ml IFN- ⁇ ; 2,000 units/ml IFN- ⁇ +10 ng/ml MEZ; 100 units/ml IFN- ⁇ (; 100 units/ml IFN- ⁇ (+10 ng/ml MEZ; serum-free medium (D-O); 2.5 ⁇ M all-trans retinoic acid: 3 ⁇ M mycophenolic acid (MPA); 16 nM 12-O-tetradecanoylphorbol-13-acetate (TPA); 1 mM 3′-5′ cAMP; 1 mM 8-bromo-3′-5′ cyclic adenosine monophosphate (8-Br-cAMP); and 10 ng/ml methyl methanesulfonate (MMS).
- CTL control
- DMSO DMSO
- 10 ng/ml MEZ 2,000 units/ml IFN- ⁇
- the reagents in (B) are: CTL, control; 1,000 units/ml IFN- ⁇ ; 1,000 units/ml IFN- ⁇ ; 1,000 units/ml IFN- ⁇ (; 1 ng/ml IL-6; 10 ng/ml epidermal growth factor (EGF); 10 ng/ml transforming growth factor- ⁇ (TGF- ⁇ ); 2.5 ng/ml transforming growth factor-13 (TGF- ⁇ ); 1 ng/ml TNF- ⁇ ; and 10 ng/ml platelet-derived growth factor (PDGF).
- C Nuclear run-on assays for mda-5. Nuclei were prepared from HO-1 melanoma cells treated with the indicated reagents for 4 hours.
- RNA samples were extracted from HO-1 melanoma cells pretreated with 50 nM staurosporine or 0.2 ⁇ M Ro31-8220 (Calbiochem) for 30 min and treated with the indicated reagents for 8 h. RNA sample preparation and Northern hybridization were performed as described in Materials and Methods.
- FIG. 6 (A-B). Protein expression of mda-5 and intracellular localization.
- B Intracellular localization of mda-5 protein. Transiently transfected 293 cells on cover slips with the indicated fusion protein constructs were mounted and photographed using fluorescent confocal microscopy (x400).
- FIG. 7 Effect of ectopic expression of mda-5 on HO-1 cells.
- Cells were transfected with the indicated expression vector, replated 2 days later, and selected with G418.
- A Representative colony-forming assays. G418-resistant colonies transfected with the indicated expression vectors are shown. Ctl, control; AS, antisense.
- FIG. 8 (A-D). ATPase activity of MDA-5.
- A Electrophoretogram of purified proteins. GST and GST-MDA-5 were resolved on 9% SDS/PAGE and stained with Coomassie brilliant blue.
- B Effect of divalent metal ions and RNA concentration on MDA-5 ATPase activity. ATPase activity assay was performed with variable poly(I):poly(C) concentrations (0.038, 0.375, 3.75, 37.5, and 375 ng/ ⁇ l). MnCl 2 (3 mM, ⁇ ) substituted for MgCl 2 (3 mM, ⁇ ). The results were quantitated by Phosphorlmager. The data shown are the mean ⁇ SD from two experiments.
- FIG. 9 Nucleic acid sequence of mda-5p (SEQ ID NO:4).
- FIG. 10 Amino acid sequence of protein encoded by mda-5p (SEQ ID NO:7).
- FIG. 11 Nucleic acid sequence encoding an MDA-5 protein (SEQ ID NO:8).
- FIG. 12 Amino acid sequence (SEQ ID NO:9) of MDA-5 protein encoded by SEQ ID NO:8.
- a “mda-5 nucleic acid” is a nucleic acid which comprises (i) the nucleic acid sequence as set forth in FIG. 1 (SEQ ID NO:1), or (ii) a nucleic acid which encodes a protein having an amino acid sequence as set forth in FIG. 2 (SEQ ID NO:2); or (iii) a nucleic acid which hybridizes to a nucleic acid molecule having the sequence set forth in FIG. 1 (SEQ ID NO:1) under stringent conditions; and/or (iv) a nucleic acid which is at least 90 percent homologous to a nucleic acid molecule having a sequence as set forth in FIG. 1 (SEQ ID NO:1), as determined by a standard homology-assessing software program such as BLAST.
- a stringent hybridization washing solution may comprise 40 mM NaPO 4 , pH 7.2, 1-2% SDS and 1 mM EDTA. Again, a washing temperature of at least 65-68° C. is recommended, but the optimal temperature required for a truly stringent wash will depend on the length of the nucleic acid probe, its GC content, the concentration of monovalent cations and the percentage of formamide, if any, that is contained in the hybridization solution (Current Protocols in Molecular Biology, Volume I. Ausubel et al., eds. John Wiley:New York N.Y., pp. 2.10.1-2.10.16. 1989 with annual updating).
- mda-5 nucleic acid can refer to a cDNA sequence (for example, SEQ ID NO:1), to a genomic DNA sequence, or to an RNA molecule (including an antisense RNA molecule).
- a mda-5 nucleic acid may be comprised in a vector molecule, for example a virus (which may be a defective or non-defective virus) or a plasmid, phage, cosmid, etc. Additional elements to aid in replication and/or expression may be further comprised in the vector.
- a mda-5 nucleic acid may, for example, be operably linked to a promoter element which may be a mda-5 promoter or a heterologous promoter.
- a mda-5 nucleic acid may be of human or non-human species origin.
- mda-5 nucleic acid further encompasses a variant of the mda-5 nucleic acid having SEQ ID NO:1; this variant is named mda-5p and contains an additional 202 bp attached to the 3′ end of mda-5.
- the sequence of mda-5p is set forth in FIG. 9 (SEQ ID NO:4).
- Yet another variant sequence for an mda-5 nucleic acid is set forth in FIG. 11 (SEQ ID NO:8).
- a MDA-5 protein according to the invention is a protein which comprises (i) a protein having the amino acid sequence set forth in FIG. 2 (SEQ ID NO:2); (ii) a protein having the amino acid sequence set forth in FIG. 10 (SEQ ID NO:7): (iii) a protein having the amino acid sequence set forth in FIG. 12 (SEQ ID NO:9) or (ii) a protein encoded by a nucleic acid which hybridizes to a nucleic acid molecule having a sequence as set forth in FIG. 1 (SEQ ID NO:1) under stringent conditions; and/or (iii) a protein which is at least 90 percent homologous to a protein having an amino acid sequence as set forth in FIG. 2 (SEQ ID NO:2) as determined by a standard homology-assessing software program such as BLAST.
- a MDA-5 protein may be of human or non-human species origin.
- the present invention further provides for antibody molecules which specifically bind to a MDA-5 protein, which may be monoclonal antibodies, polyclonal antibodies, single chain antibodies, or fragments thereof, generated according to methods known in the art.
- a “mda-5 promoter” is a nucleic acid which comprises (i) a nucleic acid comprising the sequence set forth in FIG. 3 (SEQ ID NO:3); or (ii) a nucleic acid which hybridizes to a nucleic acid having the sequence set forth in FIG. 3 (SEQ ID NO:3) under stringent conditions; and/or (iii) a nucleic acid which is at least 90 percent homologous to a nucleic acid having a sequence as set forth in FIG. 3 (SEQ ID NO:3), as determined by a standard homology-assessing software program such as BLAST.
- a mda-5 promoter of the invention may be comprised in a vector molecule, such as a virus (defective or non-defective) or plasmid, or phage, or cosmid vector, and/or may be operably linked to a gene of interest.
- Suitable genes of interest include, but are not limited to, a mda-5 nucleic acid, or a protein which binds to a MDA-5 protein, or a tumor suppressor gene such as (but not limited to) p21, the retinoblastoma tumor suppressor gene, or p53, or a reporter gene, for example, but not limited to, luciferase or beta glucuronidase.
- ATPase activity may be measured using any method known in the art.
- ATPase may be measured using the method set forth in the working example below, as follows.
- Poly(I):poly(C) (Amersham Pharmacia) or other RNA which has been reextracted with acid phenol/chloroform and precipitated may be used as a substrate for the reaction; for example, variable poly(I):poly(C) concentrations (0.038, 0.375, 3.75, 37.5, and 375 ng/ ⁇ l) may be used.
- the results may be quantitated by PhosphorImager.
- the reaction may be initiated by addition of the ATP mixture and the dissociated Pi may be resolved in polyethylene imine cellulose TLC plates as described (Wagner et al., 1998; EMBO J. 17:2926-2937).
- the present invention provides for methods of protecting against or limiting viral infection in a subject comprising administering, to the subject, an agent which increases the level of MDA-5 protein activity in the subject.
- Protecting against contracting a viral infection does not require that there be absolute protection; for example, substantially decreasing the likelihood of infection, for example reducing the risk of infection, with exposure, at least 2-fold, is considered protection.
- “Limiting viral infection”, as defined herein, refers to any one or more of decreasing the number of cells infected by a virus within a subject or among several subjects; decreasing the cytopathic effect caused by a virus, decreasing the amount of viral replication, decreasing the clinical severity of a viral infection, and/or decreasing the period of time that a subject suffers from a viral infection.
- Increasing the level of MDA-5 protein activity in the subject encompasses increasing the level of MDA-5 protein activity in at least some but not necessarily all cells, tissues, and/or fluids of the subject.
- the level of MDA-5 protein activity may be measured directly or indirectly, for example, but not by way of limitation, by measuring the amount of MDA-5 protein, the amount of ATPase activity, and/or the amount of MDA-5 encoding mRNA.
- the present invention provides for a method of protecting against or limiting viral infection in a subject comprising administering, to the subject, a therapeutically effective amount of an agent which increases MDA-5 protein-mediated RNA degradation in the subject.
- the present invention provides for methods of protecting against or limiting viral infection in a subject comprising administering, to the subject, a therapeutically effective amount of an agent which increases ATPase activity in the subject.
- agents which may be used to increase the level of MDA-5 protein, or MDA-5 protein-mediated RNA degradation, or ATPase activity in a subject include, but are not limited to, (i) MDA-5 proteins; (ii) mda-5 nucleic acids, in expressible form, which encode MDA-5 proteins; (iii) agents which increase the activity of an mda-5 promoter or that stabilize MDA-5 encoding mRNA; (iv) agents which increase the RNA degradation activity of MDA-5 protein; and (v) agents which increase ATPase activity of MDA-5 protein.
- a therapeutic amount of MDA-5 protein may be administered to a subject by any suitable route, including intravenously, intramuscularly, orally, or by inhalation, so as to supply cells which are infected or at risk of being infected with the protein.
- the MDA-5 protein may be comprised in a vehicle which aids cellular uptake and/or inhibits protein degradation, for example, in liposomes or microspheres.
- an effective amount of MDA-5 protein may be administered to a subject who has been or may be in contact with a virus spread by the respiratory route in the form of an inhaled aerosol spray.
- a mda-5 nucleic acid may be administered in expressible form, for example, in the form of “naked DNA” or comprised in a vector, for example a viral vector.
- the virus may be an adenovirus, such as, for example, a replication-defective adenovirus.
- the mda-5 nucleic acid may be operably linked to a suitable promoter, which may be an mda-5 promoter or a heterologous promoter, such as the cytomegalovirus immediate early promoter, the Rous sarcoma virus long terminal repeat promoter, the human elongation factor ⁇ 1 ⁇ promoter, the human ubiquitin c promoter, etc.
- an inducible promoter may be desirable, in certain embodiments of the invention, to use an inducible promoter.
- inducible promoters include the murine mammary tumor virus promoter (inducible with dexamethasone); commercially available tetracycline-responsive or ecdysone-inducible promoters, etc.
- an effective amount of an mda-5 nucleic acid, operably linked to a promoter sequence, comprised in a viral vector such as a replication defective adenovirus vector may be administered to a subject who has been or may be in contact with a virus spread by the respiratory route in the form of an inhaled aerosol spray.
- the amount of virus administered may be 10 9 -1013 plaque forming units.
- an effective amount of a second agent may be administered to the subject before, during, or after administration of MDA-5 protein or mda-5 nucleic acid.
- the second agent is defined as a facilitator of MDA-5 activity. Examples include, but are not limited to, interferon alpha, interferon beta, interferon gamma, poly(I)(C) and tumor necrosis factor alpha.
- a third agent which promotes mda-5 activity may be additionally administered; for example, but not by way of limitation, if one of the above interferons is used as second agent, another one of these interferons may be used as third agent, or mezerein may be used.
- an effective amount of an antiviral agent is administered to improve the net antiviral defense.
- the amount of antiviral activity achieved is greater that the amount associated with the antiviral agent used without an mda-5 related molecule.
- antiviral agents include, but are not limited to, (i) amantadine, rimantidine, and sialic acid analogues such as zanamivir or other inhibitors of influenza sialidase for the specific inhibition of influenza viruses; (ii) Aayclovir (Zovirax), ganciclovir, valacyclovir (Valtrex), lamivudine (3TC; Epivir) or other nucleoside analogs such as vidarabine for the treatment of herpesvirus infections (HSV-1, HSV-2, VZV (chicken pox), EBV and CMV); (iii) foscamet (Foscavir), a pyrophosphate analog, may be useful in the treatment of the above-mentioned herpesviruses, and also may useful in the treatment of retroviruses including HIV-1; (iv) zidovudine (Retrovir or AZT), didanosine, zalcitabine and related purine analogues such as riba
- Lassa fever or bunyaviruses (e.g. Hantavirus), respiratory syncytial virus (RSV) and in the treatment of Hepatitis C; the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune) may also be useful in the treatment of HIV-1);
- indinavir (Crixivan), saquinavir (Fortovase) and other HIV protease inhibitors for the treatment of retroviruses including HIV-1;
- monoclonal antibody inhibitors of ICAM-1 for the treatment of rhinoviruses, the most common cause of colds; and
- zintevir an HIV integrase inhibitor, for the treatment of HIV-1.
- an agent which activates an mda-5 promoter may be used to increase transcription of the endogenous mda-5 gene.
- agents include certain second agents, facilitators of MDA-5 activity, described above, such as interferon alpha, interferon beta, interferon gamma, tumor necrosis factor alpha, and poly IC. According to this set of embodiments they are administered without an mda-5 nucleic acid or an MDA-5 protein, although administration of an mda-5 promoter activating agent may be combined with one or more other facilitator of MDA-5 activity which does not act at the transcriptional level, and/or with one or more antiviral agent.
- the invention provides for an assay for identifying an activator of an mda-5 promoter, comprising (i) preparing a nucleic acid construct having an mda-5 promoter operably linked to a reporter gene (defined herein as a gene having a detectable product) for example, but not limited to, a luciferase gene; (ii) introducing the construct into a cell, such as a eukaryotic cell, for example, but not limited to, an HO-1 cell; (iii) exposing the cell to a test agent; (iv) measuring the amount of reporter gene product produced by a cell exposed to the test agent; and (v) comparing the amount of reporter gene product produced by a cell exposed to the test agent to the amount of reporter gene product produced by a cell containing the mda-5 promoter carrying construct which has not been exposed to the test agent.
- a reporter gene defined herein as a gene having a detectable product
- a reporter gene defined herein as a gene having a detect
- the cell (generally in a cell culture or organism) exposed to the test agent and the cell not exposed to the test agent should otherwise be maintained under the same or similar conditions.
- An increase in the level of reporter gene product in a cell exposed to the test agent has a positive correlation with an increase in mda-5 promoter activity.
- a therapeutic amount of an agent which increases the RNA degradation activity of MDA-5 protein may be administered to a subject.
- the present invention further provides for methods of identifying agents which increase the RNA degradation activity of MDA-5 protein.
- proteins which form physical associations with MDA-5 may be identified, for example, by a yeast two-hybrid assay, or by computerized analysis which predicts interactions between proteins. After identifying a protein which associates with MDA-5, the ability of the identified protein to degrade RNA either alone or in combination with MDA-5 may be tested.
- the present invention further provides for the administration of agents which increase ATPase activity, for example, agents which increase the ATPase activity of MDA-5.
- agents which increase ATPase activity of MDA-5 for example, agents which increase the ATPase activity of MDA-5.
- the present invention provides for assays for identifying such agents, which comprise combining, in an ATPase assay, MDA-5 protein and a test agent, measuring the ATPase activity of MDA-5 plus test agent, and comparing the resulting ATPase activity to the ATPase activity of the same amount of MDA-5 in the absence of the test agent.
- infections which may be treated by the foregoing methods are those caused by 1) picomaviruses, a family of viruses that includes polioviruses, Coxsackie viruses, rhinoviruses, enteroviruses, and hepatitis A virus, which can cause poliomyelitus, meningitis, and hepatitis (hepatitis A) in humans, 2) caliciviruses, a family of viruses that include the mild gastroeneteritis-inducing Norwalk group of viruses, 3) astroviruses, which can cause severe gastroenteritis, 4) togaviruses, a family of viruses that includes the alphaviruses, the cause of polyarthritis and a variety of encephalitidies including Eastern and Western equine encephalitis, and rubiviruses, the cause of rubella (German measles), 5) flaviviruses, a family of viruses including flaviviruses, pestiviruses and hepatitis C virus
- coronaviruses a family of viruses including the coronaviruses, a cause of colds in humans and feline infectious peritonitis in cats, and the toroviruses, 7) arteriviruses, 8) paramyxoviruses, a family of viruses including paramyxoviruses, rubulaviruses, morbilliviruses and pneumonoviruses, which can cause measles and mumps, 9) rhabdoviruses, a family of viruses including rhabdoviruses, vesciculoviruses, lyssaviruses, ephemeroviruses, cytorhabdoviruses and nucleorhabdoviruses, which can cause vescicular s
- a virus produces a helicase
- providing increased levels of MDA-5 by one of the foregoing methods may be used to compete with the viral helicase, which would be desirable where this competition would result in inhibition of the viral helicase and have a negative effect on viral replication and/or pathogenesis.
- Such negative competition would occur, for example, where the viral helicase has greater ATPase activity relative to MDA-5, and/or where the viral helicase has a different binding affinity for target RNA relative to MDA-5. Such characteristics may be evaluated using standard laboratory techniques.
- viruses which encode helicase molecules are poxviruses such as vaccinia, alphaviruses such as Semliki Forest virus (SFV), flaviviruses such as hepatitis C virus (HCV), reoviruses such as human rotaviruses A and B, and picomaviruses such as polio virus, among others.
- poxviruses such as vaccinia, alphaviruses such as Semliki Forest virus (SFV), flaviviruses such as hepatitis C virus (HCV), reoviruses such as human rotaviruses A and B, and picomaviruses such as polio virus, among others.
- the present invention provides for methods of inhibiting cell proliferation and/or promoting apoptosis of a cell population or in a subject comprising administering, to the cell population or subject, an agent which increases the level of MDA-5 protein activity in the subject.
- Inhibiting cell proliferation and/or promoting apoptosis means decreasing the increase in the number of cells in a population over a time interval, relative to a control population in which the level of MDA-5 protein has not been increased over the same length of time, by at least about 20 percent.
- “Increasing the level of MDA-5 protein in the subject” encompasses increasing the level of MDA-5 protein in at least some but not necessarily all cells, tissues, and/or fluids of the subject.
- the present invention provides for methods of inhibiting tumor growth in a subject comprising administering, to the subject, an effective amount of an agent which increases the level of MDA-5 protein activity in the subject.
- agents which may be used to increase the level of MDA-5 protein activity include, but are not limited to, (i) MDA-5 proteins; (ii) mda-5 nucleic acids, in expressible form, which encode MDA-5 proteins; (iii) agents which increase the activity of an mda-5 promoter or that stabilize MDA-5 encoding mRNA; and (iv) agents which increase the RNA degradation activity of MDA-5 protein. These agents have been described in the foregoing section.
- an interferon such as interferon alpha, interferon beta, or interferon gamma.
- the foregoing agents may be administered in conjunction with one or more additional anti-neoplastic agent, including, but not limited to, a chemotherapeutic agent, immunotherapy, radiation therapy, and the like.
- additional anti-neoplastic agent including, but not limited to, a chemotherapeutic agent, immunotherapy, radiation therapy, and the like.
- malignancy which may be treated according to the present invention include, but are not limited to, melanoma, glioblastoma multiforme, neuroblastoma, astrocytoma, osteosarcoma, breast cancer, cervical cancer, colon cancer, lung cancer, Kaposi's sarcoma, hairy cell leukemia, nasopharynx cancer, ovarian cancer, and prostate cancer.
- the present invention also provides for the use of MDA-5 to sensitize a cell to the growth inhibitory and/or apoptosis-promoting effect(s) of a protein kinase C inhibitor (including, but not limited to, mezerein).
- a protein kinase C inhibitor including, but not limited to, mezerein.
- one of the foregoing agents which increase MDA-5 protein activity may be administered prior to, coincident with, or after administering a protein kinase C inhibitor.
- Such methodology may also be used to eliminate virus-infected cells.
- new inhibitors of protein kinase C may be identified by their ability to inhibit cell proliferation/promote apoptosis in the context of increased MDA-5 protein activity.
- a mda-5 promoter may be used to deliver and express genes targeting virally infected cells for destruction.
- the mda-5 promoter could be used in a virus comprising a first cancer-inhibitory gene (e.g., p53, mda-7) operably linked to a promoter selectively active in cancer cells (e.g., PEG-3), and further comprising a second cancer-inhibitory gene (e.g., IL-2, interferon gamma, interleukin 12) operably linked to a mda-5 promoter.
- a virus would have cancer targeted specificity (due to the first promoter) and IFN or similar inducing agent induction potential (due to the mda-5 promoter, thereby augmenting the killing of cancer cells.
- HO-1 human melanoma cells and 293 cells were grown as described (Fisher et al., 1985, J. Interferon Res 5:11-22). Sf9 cells were cultured in TNM-FH medium (Mediatech Laboratories, Cody, N.Y.) supplemented with 10% FBS and penicillin/streptomycin (100 units/100 ⁇ g/ml) at 27° C. in a humidified incubator.
- TNM-FH medium Mediatech Laboratories, Cody, N.Y.
- penicillin/streptomycin 100 units/100 ⁇ g/ml
- mda-5 Cloning and Sequencing of mda-5.
- a partial mda-5 cDNA (3′, 1.8 kb) was cloned by screening a human placental cDNA library (CLONTECH; Ausubel et al., 1992. Short Protocols in Molecular Biology. Wiley:New York).
- the remaining 5′ region of the mda-5 cDNA (1.5 kb) was obtained by using a modified rapid amplification of cDNA ends approach.
- This approach involved an anchor primer instead of poly(A) or (G) tailing designed to anneal to the 5′ end of the mda-5 cDNA, followed by second-strand synthesis and subsequent PCR using an mda-5-specific reverse transcription primer to generate a full-length mda-5 cDNA.
- RNA preparation and Northern blot hybridization were performed as described (Ausubel et al., 1992. Short Protocols in Molecular Biology. Wiley:New York).
- Northern blots were probed with a 32 P-labeled 2.5-kb EcoRI fragment of mda-5 cDNA and a 0.7-kb glyceraldehyde-3-phosphate dehydrogenase fragment.
- Nuclear run-on assays were performed as described (Ausubel et al., 1992. Short Protocols in Molecular Biology. Wiley:New York).
- Probes used for nuclear run-on assays included: mda-5 5′, 9-837 bp; mda-5 3′, 2,531-3,365 bp; and a glyceraldehyde-3-phosphate dehydrogenase fragment (0.7 kb). Autoradiograms were quantitated by densitometry using a Molecular Dynamics densitometer.
- mda-5 Expression Vectors A hemagglutinin (HA)-tagged mda-5 fragment was obtained by reverse transcription-PCR, using primers 5′-GCCACCATGTACCCATACGACGTCCCAGACTACGCTATGTCGAATGGGTATT CCACAGACG-3′ (SEQ ID NO:5) and 5′-TCACTAATCCTCATCACTAAATAAACAGC-3′ (SEQ ID NO.:10), and was cloned into the EcoRV site of pcDEF3 with expression regulated by the EF-1 ⁇ promoter.
- HA hemagglutinin
- An antisense mda-5 expression vector was constructed by cloning the EagI/SpeI mda-5 genomic DNA (3.8-kbp) fragment from a bacterial artificial chromosome clone into the SpeI/NotI site of pcDEF3.
- the genomic DNA fragment consists of the first exon and part of the first intron.
- a green fluorescent protein (GFP)-mda-5 fusion expression vector was constructed by ligation of an mda-5 cDNA product, derived by reverse transcription-PCR using the primers 5′-ATGTCGAATGGGTATTCCACAGACG-3′ (SEQ ID NO:6) and 5′-TTTTTTTTTTTTCAGAGTAAAACAATC-3′ (SEQ ID NO.:11), into the SmaI site of pEGFP-C2 (CLONTECH).
- MDA-5 fusion proteins were probed with either ⁇ -HA antibody (Roche Diagnostics) or ⁇ -GFP antibody (CLONTECH) and with horseradish peroxidase-conjugated anti-Mouse IgG (Sigma) and detected by ECL (Amersham Pharmacia).
- ⁇ -HA antibody Roche Diagnostics
- ⁇ -GFP antibody CLONTECH
- ECL horseradish peroxidase-conjugated anti-Mouse IgG
- ECL Ampercutaneous plasmids
- 10 5 cells per well were seeded in 6-well plates containing a cover glass and transfected with the indicated plasmids (pEGFP-C2 and pEGFP-C2/mda-5, 2.5 ⁇ g per well).
- fluorescence microscopy the cover glass containing transfected cells was washed with PBS and mounted onto a glass slide with mounting medium. The cells were observed by fluorescent confocal microscopy.
- HO-1 melanoma cells were plated at 8 ⁇ 10 5 in a 6-cm dish 1 day before transfection with 5 ⁇ g of supercoiled plasmid DNA. Two days after transfection, cells were trypsinized and replated at 10 5 cells per 6-cm dish with complete medium containing 750 ⁇ g of G418/ml. The G418-containing medium was replaced once a week for 3 weeks. Cells were fixed with methanol ( ⁇ 20° C.) and stained with Giemsa (Sigma). Colonies with more than 50 cells were enumerated.
- Glutathione 5-Transferase (GST)-MDA-S Fusion Protein A baculovirus transfer vector of GST-MDA-5 was constructed by ligation of the XhoI-BamHI mda-5 fragment from the pEGFP-C2/mda-5 and XhoI BgIII sites of pAcGHLT-C (PharMingen). The transfer vectors of GST only and GST-MDA-5 fusion (5 ⁇ g each) were transfected into Sf9 cells, and recombinant virus producer cells were selected as described by the manufacturer (PharMingen). GST and GST-MDA-5 fusion proteins were expressed and purified by affinity chromatography with glutathione-Sepharose 413 as described by the manufacturer (PharMingen).
- IFN- ⁇ +MEZ Induces Terminal Differentiation in HO-1 Cells.
- Treatment of HO-1 melanoma cells with IFN- ⁇ (2,000 units/ml) plus MEZ (10 ng/ml) results in rapid and irreversible growth suppression, induction of dendrite-like processes, and enhanced melanogenesis (Fisher P B et al., 1985, J. Interferon Res 5:11-22; Jiang H et al., 1993, Mol Cell Different 1:41-66).
- This combination treatment also results in a subset of detached cells that display A o DNA content by fluorescence-activated cell sorter analysis, which is indicative of apoptosis. These floating cells are apparent first at 48 h.
- treatment with either agent alone inhibits growth and melanogenesis in a reversible manner, and treated cells do not terminally differentiate or undergo apoptosis.
- induction of terminal differentiation in HO-1 cells by the combination treatment would be anticipated to involve the induction of genes that are relevant to the mode of action of the individual inducing agents, i.e. IFN- ⁇ and MEZ, related to both reversible and terminal differentiation, and associated with apoptosis (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang H et al., 1993, Mol Cell Different 1:41-66; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-156).
- the cloned mda-5 cDNA [3,365 bp, excluding the poly(A) tail] contains a 1,025-amino acid-encoding ORF (nucleotides 169-3,246) with a predicted molecular mass of 116.7 kDa and a pI of 5.44.
- the first AUG at position 169 likely represents a genuine start codon caused by the presence of an in-frame stop codon at nucleotide 159 and an A ⁇ 3 Kozak consensus sequence (AXXaugG; Kozak M, 1996, Mamm Genome 7:563-574).
- a polyadenylation signal (AATAAA) is located 23 by upstream of the poly(A) tail.
- In vitro translation of the mda-5 cDNA resulted in a protein with apparent molecular mass of 120 kDa and additional smaller bands, most likely truncated translation products of MDA-5.
- the ProDom database recognizes 10 cloned or hypothetical proteins closely related in their helicase domain to MDA-5 (dating back to early prokaryotes: Methanobacterium thermoautotrophicum, 027466; Schizosaccharomyces pombe , Q09884; Caenorhabditis elegans , Q17545, Q44165, and P34529; Arabidopsis thaliana , Q9SP32; Sus scrofa , RHIV-1; and Homo sapiens , RIG-1, Q9HAM6, and Q9UPY3). Proteins except RIG-7 (Sun Y W, 1995, In Sanghai Institute of Hematology.
- MDA-5 is the first protein with documented RNA-dependent ATPase activity ( FIG. 8 ).
- RNA helicases impinge on many biological phenomena including cell differentiation, proliferation, development, and viral life cycle (Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-296; Jankowsky and Jankowsky, 2000, Nucleic Acids Res 28:333-334). Although RNA helicases are well conserved in their ATPase and helicase motifs, a direct correlation between sequence motifs and function is not clear-cut. In this context, it is not possible to deduce the potential functions) of MDA-5 based on its primary structure.
- RNase III is an enzyme targeting double-stranded RNA and is involved in gene silencing by RNA interference (Bernstein et al., 2001, Nature 409(6818):363-6).
- MDA-5 through its ATP-dependent unwinding of RNA, most likely functions to promote message degradation by specific types of RNase.
- RIG-1 is expressed during all-trans retinoic acid-induced promyelocytic differentiation (Sun Y W, 1995, In Sanghai Institute of Hematology. Rui - Jin Hospital (Sanghai Second Medical University, Sanghai, China)) and also is induced by IFN- ⁇ in HO-1 cells.
- the expression of RHIV-1 is induced by viral infection suggesting IFN inducibility (Zhang et al., 2000, Microb Pathog 28:267-278).
- Q93P32 (also known as CAF) seems to suppress cell division in floral meristems (Jacobsen et al., 1999, Development 126:5231-5243).
- mda-5 is expressed during differentiation induced by IFN-/3 plus MEZ, which also involves growth inhibition.
- the putative helicases of this subgroup may participate in similar biochemical changes associated with growth inhibition and differentiation.
- MDA-5 A distinctive attribute of MDA-5 involves the N-terminal one-third of this molecule.
- This region of the MDA-5 protein contains a CARD (amino acids 125-174), with significant but relatively low probability (P 0.04).
- the CARD is a structural motif that consists of amphipathic ⁇ -helices and is present in various pro- and antiapoptotic molecules (Hofmann et al., 1997, Trends Biochem Sci 22:155-156). The recruitment of caspase to apoptotic signaling receptor complexes through CARD-CARD interactions has been documented (Chou et al., 1998, Cell 94:171-180).
- MDA-5 N-terminal 50 amino acids (125-174) of MDA-5 do not align with other CARD proteins, probably because CARD is a structural motif, secondary structure analysis of amino acids 101-200 of MDA-5 with secondary structural content prediction indicates 83.3% ⁇ -helical contents in this area. Based on these considerations, it is likely that the MDA-5 N terminus contains a CARD, and would represent the first RNA-modulating molecule associated with programmed cell death.
- mda-5 Expression Analysis Because mda-5 was cloned in the context of induction of growth arrest and both reversible and terminal differentiation in HO-1 cells, experiments were performed to determine the effect on expression of agents affecting these parameters. Of the agents tested that influence melanocytic differentiation in human melanoma cells (Kang et al., 2001, Gene 267:233-242; FIG. 5A ) and modulate melanoma growth (Garbe et al., 1993, J. Invest Dermatol 100:239S-244S; FIG. 5B ), only IFNs ( ⁇ , ⁇ , and ⁇ and TNF- ⁇ significantly increased steady-state mda-5 transcript levels within 24 h.
- IFN- ⁇ the magnitude of induction by IFN- ⁇ was at least 3-fold greater than with IFN- ⁇ , IFN- ⁇ , and TNF- ⁇ .
- Induction of DNA damage by exposure to the alkylating agent methyl methanesulfonate or growth in serum-free medium for 24 h did not induce mda-5 expression.
- MEZ treatment for 24 h by itself did not induce mda-5 expression, it augmented mda-5 expression by 1.5-fold when used in combination with IFN- ⁇ or IFN-(( FIG. 5A ).
- mda-5 is an IFN- and TNF- ⁇ -responsive gene, it responds primarily to IFN- ⁇ treatment.
- the timing of mda-5 expression was studied also by Northern blotting, indicating induction of mda-5 mRNA by 2 h of treatment with IFN- ⁇ or IFN- ⁇ +MEZ.
- the mda-5 message level peaked between 6 and 8 h and remained elevated over a 96-h period.
- MEZ further increased mda-5 message level above that observed with IFN- ⁇ alone, it did not affect the timing of mda-5 expression.
- Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) did not inhibit the induction of mda-5 by IFN- ⁇ or IFN- ⁇ +MEZ.
- mda-5 expression was ⁇ 2-fold higher in placenta, pancreas, and spleen than other organs, no organ manifested significantly high enough expression to suggest a correlation between mda-5 expression and specific organ function.
- Northern blot analysis of mda-5 expression in cancer and normal cell lines of various sources again indicated low basal levels of expression with strong induction by IFN- ⁇ .
- IFN- ⁇ and IFN- ⁇ +MEZ induce 3-fold lower levels of mda-5 mRNA than IFN- ⁇ and IFN- ⁇ +MEZ, but these treatments also directly induce mda-5 expression without prior protein synthesis. It is possible that the mda-5 promoter contains an IFN- ⁇ response sequence such as GAS (Stark et al., 1998, Annu Rev Biochem 67:227-264).
- the signal generated by IFN- ⁇ may impact on mda-5 expression through shared signaling components with IFN- ⁇ but not through IFN- ⁇ production.
- TNF- ⁇ activates the Janus kinase/signal transducer/activator of transcription signal transduction (Jak/STAT) pathway, which is stimulated by type I IFNs (Guo et al., 1998, J. Immunol 160:2742-2750).
- Jak/STAT transcription signal transduction pathway
- TNF- ⁇ may induce mda-5 expression in HO-1 cells by activation of Jak/STAT signals as found in 3T3-L1 cells. Therefore, the Jak/STAT signal transduction pathway seems to be a major contributor to mda-5 expression.
- IFNs were identified initially as molecules that provide immediate protection against viral infection by eliciting an antiviral state in exposed cells (Stark et al., 1998, Annu Rev Biochem 67:227-264). IFN treatment evokes diverse responses depending on the target cell including growth inhibition, changes in differentiation, induction or inhibition of apoptosis, and changes in the expression of immune system modulating genes (Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-56; Stark et al., 1998, Annu Rev Biochem 67:227-264; Grant et al., 1985, Biochem Biophys Res Commun 130:379-388; Greiner et al., 1985, Pharmacol Ther 31:209-236).
- mda-5 plays a critical role in responses that are specific for IFN signaling such as antiviral effect, growth inhibition, and apoptosis but may be less critical during normal physiological processes.
- MDA-5 may interact with death molecules through CARD and participate in the IFN- and/or TNF- ⁇ -induced apoptotic process by modulating RNA structure.
- MDA-5 also could have multiple functions with one or more of its potential enzymatic activities predominating, depending on the cellular context and presence of other coeffectors, e.g. CARD-containing proteins.
- IFN- ⁇ +MEZ potentiate mda-5 mRNA levels suggests cooperativity between IFN and MEZ signaling in regulating mda-5 expression.
- MEZ is an activator of PKC
- a potential role for PKC in enhancing mda-5 expression after IFN- ⁇ +MEZ treatment was tested by pretreatment of HO-1 cells with PKC-specific inhibitors, staurosporine or Ro31-8220 (Tamaoki et al., 1986, Biochem Biophys Res Commun 135:397-402; Morreale et al., 1997, FEBS Lett 417:38-42; FIG. 5D ). Both reagents abolish the enhanced mda-5 induction by combination treatment.
- FIG. 6A Confocal fluorescence microscopy of 293 cells transiently transfected with GFP-MDA-5 fusion protein demonstrated that the protein localizes in the cytoplasm.
- FIG. 6B The cytoplasmic localization of the MDA-5 protein corresponded with the absence of a nuclear localization signal in the MDA-5 protein. No specific localization pattern within the cytoplasm of the GFP-MDA-5 fusion protein was apparent. Cytoplasmic localization of MDA-5 suggests that MDA-5 plays a role in the translation, sequestration of specific mRNAs, or in regulating mRNA stability.
- mda-5 Inhibits the Colony-Forming Ability of HO-1 Cells.
- mda-5 is induced primarily by IFN- ⁇ in HO-1 cells, ectopic expression of mda-5 could mimic the effect of IFN- ⁇ 3 treatment and inhibit growth.
- the mda-5 gene was expressed in HO-1 cells by transfection, and colony-forming ability was determined ( FIGS. 7A and B).
- MDA-5 ATPase Activity of MDA-5.
- a GST-fusion protein of MDA-5 was purified by glutathione-Sepharose affinity chromatography and the purified GST-MDA-5 migrates as a single protein in SDS-PAGE with an apparent molecular mass of 170 kDa ( FIG. 8A ).
- GST as a control was expressed and purified in a manner similar to that for GST-MDA-5 ( FIG. 8A ).
- the ATPase activity of the MDA-5 fusion protein was 2-fold more active at pH 6.5 than at pH 7.5 but strictly depended on poly(I)-poly(C) (primarily exists as a double-stranded molecule) at both pH values.
- Poly(I) ⁇ poly(C) has been shown to induce mda-5 in HO-1 and other cancer cells.
- the requirement of divalent metal ions and effective RNA concentrations for MDA-5 ATPase activity were determined at various poly(I) ⁇ poly(C) concentrations by using either Mg 2+ or Mn 2+ ( FIG. 8B ).
- the presence of Mn 2+ shifted the optimal poly(I) ⁇ poly(C) concentration for MDA-5 ATPase activity to a higher range.
- ATPase activity peaked at 3.75 ng of poly(I)-poly(C)/ ⁇ l with Mg 2+ and at 37.5 ng of poly(I) ⁇ poly(C)/ ⁇ l with Mn 2+ .
- MDA-5 The specific activity of MDA-5 at optimal conditions was calculated as 1.01 ⁇ 0.22 nmol ⁇ min ⁇ g of protein with Mg 2+ and 0.80 ⁇ 0.03 nmol ⁇ min ⁇ g of protein with Mn 2+ . These results suggest that Mg 2+ is likely to be the preferred ion for MDA-5. Unexpectedly, increasing poly(I) ⁇ poly(C) concentrations did not increase MDA-5 ATPase activity. At the highest poly(I)-poly(C) concentration tested, ATPase activity of MDA-5 was reduced to 0.20, ⁇ 0.25-fold of peak activity. Depletion of divalent metal ions by excessive poly(I) ⁇ poly(C) provides a possible explanation for this phenomenon.
- ATPase activity of MDA-5 also was determined at various ATP concentrations, and the calculated K m value for ATP as determined by double reciprocal plot between [ATP] and hydrolyzed P i fraction was 26 ⁇ M ( FIG. 8C ).
- the K m value of MDA-5 for ATP is lower than other well characterized RNA helicases including eIF4A (DEAD helicase, 160 ⁇ M; Pause et al., 1993, Mol Cell Biol 13:6789-6798), NPH-11 (DEAH helicase, 1.2 mM) (Gross and Shuman, 1996, J.
- MDA-5 is strictly an RNA-dependent ATPase, the activity of which may be limited more by the presence of double-stranded RNA than by [ATP]. These results also reinforce the suggestion that MDA-5 is an ATP-dependent RNA helicase.
- MDA-5 ATPase activity of MDA-5 was measured in the presence of cellular RNA samples.
- cellular RNA samples Of interest, no significant ATPase activity was observed with total, either poly(A) or poly(A)-negative RNA, from IFN-treated HO-1 cells and yeast tRNA (20 ng/ ⁇ l in FIG. 8D ; 375 ng/ ⁇ l).
- poly(A) or poly(A)-negative RNA from IFN-treated HO-1 cells and yeast tRNA (20 ng/ ⁇ l in FIG. 8D ; 375 ng/ ⁇ l).
- the lack of a stimulatory effect on MDA-5 ATPase activity by cellular RNA may reflect the heterogeneous nature of the cellular RNA populations or the extent of double-stranded RNA.
- rRNA and tRNA are highly double-stranded and relatively homogeneous in comparison with poly(A) RNA, they did not activate MDA-5 ATPase activity, thereby ruling out these molecules as potential substrates for MDA-5. ATPase activity was apparent also with poly(A, U), which was significantly higher than with poly(I, U), suggesting no specific preference for inosinic acid.
Abstract
The present invention relates to mda-5 nucleic acids, MDA-5 proteins, the mda-5 promoter, and related molecules, and the use of each of these elements in protecting against or limiting viral infection, controlling cell proliferation, and promoting apoptosis. It is based upon the discovery that, contrary to earlier hypotheses based on the amino acid sequence of MDA-5, the protein is not a defective ATPase but rather exhibits ATPase activity. This supports the role of MDA-5 as a RNA helicase protein and consequently its use in promoting RNA degradation, for example in the context of antiviral defense, limitation of cell proliferation, or induction of apoptosis.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/055,475, filed Jan. 22, 2002 which is a continuation-in-part of International Patent Application No. PCT/US01/06960, filed Feb. 28, 2001 and published in English on Sep. 7, 2001 as Publication No. WO 01/64707, which is a continuation-in-part of U.S. patent application Ser. No. 09/515,363, filed Feb. 29, 2000.
- The subject matter described herein was developed at least in part using funds provided by National Institutes of Health Grants CA35675 and CA74468, so that the United States Government has certain rights to this patent application.
- The present invention relates to melanoma differentiation associated gene-5 (mda-5) nucleic acids, MDA-5 proteins, and the mda-5 gene promoter and related molecules, and the use of these elements to protect against or limit viral infection, to control cell proliferation and to induce apoptotic cell death. It is based, at least in part, on the discovery that MDA-5 protein exhibits ATPase activity.
- Terminal differentiation is essential for normal development and homeostasis (Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-56). However, this process can go awry in cancer cells, resulting in uncontrolled proliferation and an inability to respond to normal growth-inhibitory signals (Fisher et al., 1985, Pharmacol Ther 27(2):143-66; Waxman S., 1995, Differentiation Therapy, Waxman, ed., Sereno Symposium Publications: Rome, Italy. pp. 1-531). Moreover, as cancer cells evolve, ultimately developing new phenotypes or acquiring a further elaboration of pre-existing transformation-related properties, the expression of differentiation-associated traits often undergoes a further decline.
- Based on these observations, a new rationale for cancer therapy is being explored, in which tumor cells are treated with agents that induce differentiation and a loss of cancerous properties, a strategy called “differentiation therapy” (Waxman et al., 1988, In: The Status of Differentiation Therapy of Cancer, Waxman et al., eds., Raven Press: New York, N.Y. pp. 1-422; Waxman et al., 1991, In: The Status of Differentiation Therapy, Vol. 1, Waxman et al., eds., Raven Press: New York, N.Y.; Jiang et al., 1994, Mol Cell Different 2:221-239; Waxman, 1995, Differentiation Therapy Waxman, ed., Sereno Symposium Publications: Rome, Italy. pp. 1-531). In principle, differentiation therapy may prove less toxic than currently employed chemotherapeutic approaches, including radiation and treatment with toxic chemicals. The clinical application of differentiation therapy will require the identification of the genes and pathways involved in determining cell fate, as well as the development of appropriate in vitro and in vivo model systems for identifying and characterizing the appropriate agent or agents that can modulate differentiation in cancer cells without causing undue toxicity to normal cells.
- Treatment of human melanoma cells with a combination of recombinant human fibroblast interferon (IFN-β) and the anti-leukemic compound mezerein (MEZ), an activator of protein kinase C, results in a rapid and irreversible suppression of growth, an extinction of tumorigenic potential in nude mice, and the induction of terminal cell differentiation (Fisher et al., 1985, J. Interferon Res 5:11-22). This process correlates with significant changes in cellular physiology, including irreversible alterations in growth, enhanced melanogenesis, morphological changes, cell surface antigen modifications, and profound variations in gene expression (Jiang et al., 1994, Mol Cell Different 2:221-239; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-156).
- When administered alone, IFN-β or MEZ can induce specific differentiation-associated changes in melanoma cells including growth suppression, melanogenesis, and alterations in morphology. However, these changes in phenotype are fully reversible after removal of the inducer (Fisher et al., 1985, J. Interferon Res 5:11-22; Jiang et al., 1993, Mol Cell Different 1:41-66; Jiang et al., 1994, Mol Cell Different 2:221-239; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-56). In these contexts, this differentiation system represents an ideal model to study growth control, differentiation (both reversible and terminal), and tumor suppression.
- To identify genes potentially involved in the process of terminal differentiation in human melanoma cells, subtraction hybridization has been employed (Jiang and Fisher, 1993, Mol Cell Different 1:285-299). Briefly, cDNA libraries were prepared from temporal RNA samples obtained from HO-1 human melanoma cells treated with IFN-β+MEZ and control, untreated HO-1 cells and control cDNAs were subtracted away from differentiation inducer-treated cDNAs (Id.). This approach resulted in an enrichment of genes displaying elevated expression as a function of treatment with the different inducers and the induction of irreversible growth suppression and terminal cell differentiation. Screening of the subtracted differentiation inducer-treated HO-1 cDNA library identified both known and novel cDNAs displaying elevated expression in differentiation inducer treated HO-1 cells (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang et al., 1994, Mol Cell Different 2:221-239; Jiang et al., 1995, Oncogene 11(12):2477-2486; Jiang et al., 1996, Proc Natl Acad Sci USA 93:9160-9165; Lin et al., 1996, Mol Cell Different 4:317-333; Lin et al., 1998, Gene 207:105-110; Huang et al., 1999, Oncogene 18:3546-3552; Huang et al., 1999, Gene 236:125-131).
- Four classes of genes, called melanoma differentiation associated (mda) genes, have been cloned using this approach (Jiang and Fisher, 1993, Mol Cell Different 1:285-299). These include genes displaying elevated expression as a function of treatment with: IFN-β and IFN-β+MEZ (Type I mda genes); MEZ and IFN-β3+MEZ (Type II mda genes); IFN-β, MEZ and IFN-β+MEZ (Type III mda genes); and predominantly with IFN-β+MEZ (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang et al., 1994, Mol Cell Different 2:221-239). This approach has resulted in the cloning of both known and novel genes involved in important cellular processes, including cell cycle control (mda-6/p21), interferon signaling (ISG-15, ISG-54), cancer growth control (mda-7), immune interferon response (mda-9), transcription control (c-jun, jun-B), immune recognition (HLA Class I) and cell membrane processes (5 integrin, βa integrin, fibronectin) (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang et al., 1994, Mol Cell Different 2:221-239; Jiang et al., 1995, Oncogene 11:2477-2486; Jiang et al., 1995, Oncogene 10: 1855-1864; Jiang et al., 1996, Proc Natl Acad Sci USA 93:9160-9165; Lin et al., 1996, Mol Cell Different 4:317-333; Lin et al., 1998, Gene 207:105-110).
- Phage-based cDNA-subtracted libraries and a rapid subtraction hybridization (RaSH) approach have been used to define the relevant gene changes associated with induction of terminal differentiation (Jiang et al., 1993, Mol Cell Different 1:41-66; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-156). Subtraction hybridization between a temporally-spaced differentiation inducer (IFN-β+MEZ)-treated HO-1 human melanoma cDNA library and a temporally-spaced, untreated control HO-1 cDNA library identified a differentially-expressed 0.3 kb EST, designated melanoma differentiation associated gene-5 (mda-5; Jiang and Fisher, 1993, Mol Cell Different 1:285-299; U.S. Pat. No. 5,643,761 by Fisher et al., filed Oct. 23, 1993 and issued Jul. 1, 1999; International Patent Application No. PCT/US94/12160, publication No. WO 95/11986 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Oct. 24, 1994). Northern blotting analysis indicated that the mda-5 EST hybridized with an mRNA species of 3.8 kb in IFN-β+MEZ-treated HO-1 cells (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang et al., 1994, Mol Cell Different 2:221-239).
- A full-length mda-5 cDNA (
FIG. 1 ; SEQ ID NO:1) has now been cloned by using a modified rapid amplification of cDNA ends (RACE) approach (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). The cDNA is 3,365 bp in length, excluding the polyA tail. Two ATTTA motifs, which are commonly found in RNA species that are rapidly turned over, are present at positions 3,225 and 3,284. A poly A signal (AATAAA) is located 23 bp upstream of the poly A tail. - In addition, a variant of mda-5, named mda-5p (SEQ ID NO:4), which contains an additional 202 bp attached to the 3′ end of mda-5, was identified by screening a placental cDNA library (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). Since the poly A signal for mda-5p is also located 23 bp upstream of its poly A tail, while the open reading frame (ORF; see below) remains constant, mda-5p is possibly an alternatively poly-adenylated variant of mda-5.
- An ORF is present in the mda-5 cDNA which extends from nt 169 to 3,246, and encodes a predicted protein of 1,025 amino acids having a molecular mass of 116.7 kDa (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). The primary sequence of this predicted protein is shown in
FIG. 2 (SEQ ID NO:2). In vitro translation of the mda-5 cDNA results in a protein with an apparent molecular mass of 120 kDa and additional smaller bands, most likely truncated translation products of MDA-5. - The mda-5 gene is an early IFN- and tumor necrosis factor- (TNF-)-responsive gene, the transcription of which is increased by treatment with IFN-β and IFN-β+MEZ. Thus, this gene may play a significant role in IFN-induced growth suppression and/or apoptosis. Identification, cloning and analysis of upstream genomic sequences has identified an mda-5 promoter element (
FIG. 3 ; SEQ ID NO:3) and has confirmed that the mda-5 gene is responsive at the transcriptional level to induction primarily by IFN-β and dsRNA (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). - Profile scans of the MDA-5 protein reveal putative CARD (caspase recruitment domain) and RNA helicase motifs (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). Multiple sequence alignments of the CARD motif in MDA-5 using the ClustalW system indicate that this region most closely resembles the CARD of RAIDD, which is a component of YNF-R1-mediated apoptotic signalling pathway and which contains both a death domain and a CARD motif. RAIDD interacts with RIP through its death domain and with ICH-1 (caspase-2) probably via its CARD motif.
- The cellular responses induced by IFN constitute an organism's primary defense against virus infection. Upon infection, IFN gene expression is induced, IFN-encoding RNA transcripts are translated, and IFN proteins are rapidly secreted from the cell. These IFNs may then exert a variety of effects on surrounding cells, the goal of which is to protect those cells from secondary virus infection.
- A number of different IFN molecules may be produced, depending on the type of cell infected. For example, the type I IFNs, IFN-α and IFN-β, are released from infected leukocytes and fibroblasts, respectively. Type I IFNs interact with specific receptors on the cell surface, activating a signaling cascade pathway that leads to the transcriptional induction of at least 30 genes (Sen et al., 1993, Adv Virus Res 42:57-102). Two of these IFN-induced genes encode the
enzymes 2′-5′-oligoadenylate synthase (OAS) and protein kinase R (PKR). Both of these enzymes are activated by the binding of dsRNA molecules, including those present in the cell cytoplasm following the infection of the cell by certain RNA or DNA viruses (see below). The activation of OAS by dsRNA increases the synthesis of 2′-5′ oligoadenylates, which in turn activate RNase L. Activated RNase L nonspecifically degrades single-stranded RNAs and thus limits the replication of viruses with single-stranded RNA genomes or for which single-stranded RNA molecules are formed as intermediates during replication of the virus genome (Player and Torrence, 1998, Pharmacol Ther 78(2):55-113). - The activation of PKR by dsRNA leads to a number of different cellular responses. For example, activation of PKR leads to induction of type I IFN gene expression (Der and Lau, 1995, Proc Natl Acad Sci USA 92(19):8841-8845), creating a positive-feedback loop enhancing the antiviral activities of these molecules. PKR activation also triggers the phosphorylation of several cellular proteins, including the eukaryotic translation initiation factor eIF-2-α and the inhibitor of nuclear factor-KB (IκB). Phosphorylation of eIF-2-α leads to the stabilization of the complex formed between eIF-2-α and eIF-2B, preventing further translation initiating events. Thus, activation of PKR by IFN in the presence of dsRNA blocks the further synthesis of both cellular and viral proteins (Pain, 1996, Eur J Biochem 236(3):747-71). Phosphorylation of IκB results in the activation of NF-κB (Kumar et al., 1994, Proc Natl Acad Sci USA 91(14):6288-6292), which in turn induces the transcription of a host of genes whose protein products are important regulators of apoptosis, including p53, c-Myc, Fas, FasL, IRF-1 and caspase-1. Thus, PKR is an important molecule in preventing replication of viral genomes, the synthesis of virus proteins and inducing programmed cell death in virally-infected cells.
- Although initially recognized as potent antiviral agents, it is now apparent that IFNs also induce other profound cell-type specific effects, including growth inhibition, modulation of differentiation, induction or inhibition of programmed cell death (apoptosis), and regulation of immune system genes and their expression. As introduced above, the growth inhibitory and/or apoptotic effect of type I IFNs are mediated, at least in part, by modulation of RNA translation and degradation.
- Apart from PKR and OAS, described above, RNA helicases may also play important roles in diverse processes of RNA metabolism, including degradation, translation and editing. Helicases utilize the energy provided by the hydrolysis of ATP to catalyze the unwinding of nucleic acid duplexes. All of the proteins with confirmed helicase activity examined to date contain a number of conserved sequence motifs. These motifs have been used as predictors of helicase activity, leading to the identification of more than two hundred real or putative helicase proteins (Reuven et al., 1995, J Bacteriol 177(19):5393-5400).
- The large majority of helicases share at least seven motifs encoding various functional or structural domains. Examples of functional domains include the ATPase A domain, the ATPase B domain, the nucleic acid binding domain, and the helicase domain (for a review, see Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-296). Detailed comparisons of these motifs have lead to the classification of helicases into families and superfamilies (Gorbalenya and Koonin, 1993, Curr Opin Struct Biol 3:419-429). Superfamily II contains the RNA helicases and can be subdivided into the DEAD, DEAH and DExH families based on their deviating ATPase B domains (Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-96).
- In addition to the seven domains used to classify helicases, some putative or known helicase proteins also contain domains that suggest additional functions, such as RNase III activity. RNase III degrades double-stranded RNA, and has been implicated in gene silencing by RNA interference (Bernstein et al., 2001, Nature 409(6818):363-366). Thus, at least some helicases, through their unwinding of dsRNA, may promote the degradation of single stranded and double stranded RNA molecules.
- Double-stranded polynucleotides have been shown to be present in the replicative cycle of every virus studied to date, regardless of whether its genome is double-stranded or single-stranded, or composed of DNA or RNA (Kadare and Haenni, 1997, J Virol 71(4):2583-90). Thus, it is not surprising that RNA helicases of superfamily II have been identified in the genomes of many viruses, including poxviruses such as vaccinia, alphaviruses such as Semliki Forest virus (SFV), flaviviruses such as hepatitis C virus (HCV), reoviruses such as human rotaviruses A and B, and picornaviruses such as polio virus, among others.
- All viral RNA helicases studied to date exhibit NTPase activity, which is an absolute requirement for RNA unwinding. In general, the enzyme activity of virus-derived RNA helicases is further stimulated by the presence of RNA, although this feature is not universal. In viruses with dsRNA genomes, there seems to be a correlation between genome size and the presence of an RNA helicase, leading some investigators to conclude that the relative stability of the duplex forms of longer genomes must be disrupted through helicase activity to facilitate replication and translation of the virus genome.
- The genomes of approximately 80% of the positive-stranded RNA viruses studied thus far also contain at least one potential helicase. In these contexts, it would appear that the helicases may function to disrupt intramolecular base-pairing within the RNA genome or to minimize the formation of RNA duplexes during replication of the genome. Other potential functions of RNA helicases in the life-cycle of viruses include: 1) mediating the separation of duplexes or regions of secondary structure so that transcription may begin, 2) assisting in proof-reading functions during polymerase function so that fidelity is maintained during replication, and 3) disrupting secondary structures in mRNA so that ribosomal attachment can occur, thereby facilitating the initiation of translation.
- Sequence analysis of the MDA-5 protein revealed a RNA helicase signature domain which spans the C-terminal half of the molecule. (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). MDA-5 contains four unique features that could mediate functional divergence from other RNA helicases (International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, filed Feb. 28, 2001). The CARD domain of MDA-5 in its N-terminal region is not found in any previously identified helicase. The ATPase A motif of MDA-5 is unique and contains the region LPTGSGKT as opposed to the sequence found in other RNA helicases (GXXGXGKT). International Patent Application No. PCT/US01/06960 suggests that because of this sequence divergence, MDA-5 may not bind ATP effectively, and therefore may be an ATPase defective helicase, or may require a different energy source and/or metals for activity.
- The present invention relates to mda-5 nucleic acids, MDA-5 proteins, the mda-5 promoter, and related molecules, and the use of each of these elements in protecting against or limiting viral infection, controlling cell proliferation, and promoting apoptosis. It is based upon the invention contained in International Patent Application No. PCT/US01/06960, Publication No. WO 01/64707 by The Trustees of Columbia University in the City of New York, Fisher et al., inventors, which is incorporated by reference in its entirety herein, and further on the discovery that, contrary to earlier hypotheses based on the amino acid sequence of MDA-5, the protein is not a defective ATPase but rather exhibits ATPase activity. This supports the role of MDA-5 as a RNA helicase protein and consequently its use in promoting RNA degradation, for example in the context of an antiviral defense, limitation of cell proliferation, or induction of apoptosis.
-
FIG. 1 . mda-5 cDNA sequence (SEQ ID NO:1). -
FIG. 2 . MDA-5 protein sequence (SEQ ID NO:2). -
FIG. 3 . mda-5 gene promoter sequence (SEQ ID NO:3) -
FIG. 4 . Sequence alignment of putative RNA helicases. Clustal W alignment of helicase domains of putative RNA helicases that share the RNA helicase motifs with mda-5. Conserved residues in DExH group RNA helicase defined in Jankowsky and Jankowsky, 2000, Nucleic Acids Res 28:333-334, are aligned with consensus sequence (uppercase Roman numeric). Those underlined and marked with lowercase Roman numeric are for conserved motifs in this subgroup. Asterisks (*)=identical residues; colons (:)=conserved substitutions; dots (.)=semiconserved substitutions. MDA-5 (SEQ ID NO.:2); Q9HAM6 (SEQ ID NO.:12); RHIV-1 (SEQ ID NO.:13); RIG-1 (SEQ ID NO.:14); P34529 (SEQ ID NO.:15); Q9SP32 (SEQ ID NO.: 16); Q09884 (SEQ ID NO.: 17). -
FIG. 5 (A-D). Expression of mda-5. Northern blot analyses of mda-5 after treatment with melanoma differentiation-inducing reagents (A) and growth factors (B) are shown. HO-1 cells were treated with the indicated reagents for 24 hours. The concentrations in A are: control (CTL); 0.1% DMSO; 10 ng/ml MEZ; 2,000 units/ml IFN-β; 2,000 units/ml IFN-β+10 ng/ml MEZ; 100 units/ml IFN-γ (; 100 units/ml IFN-γ(+10 ng/ml MEZ; serum-free medium (D-O); 2.5 μM all-trans retinoic acid: 3 μM mycophenolic acid (MPA); 16 nM 12-O-tetradecanoylphorbol-13-acetate (TPA); 1mM 3′-5′ cAMP; 1 mM 8-bromo-3′-5′ cyclic adenosine monophosphate (8-Br-cAMP); and 10 ng/ml methyl methanesulfonate (MMS). The reagents in (B) are: CTL, control; 1,000 units/ml IFN-α; 1,000 units/ml IFN-μ; 1,000 units/ml IFN-γ(; 1 ng/ml IL-6; 10 ng/ml epidermal growth factor (EGF); 10 ng/ml transforming growth factor-α (TGF-α); 2.5 ng/ml transforming growth factor-13 (TGF-β); 1 ng/ml TNF-α; and 10 ng/ml platelet-derived growth factor (PDGF). (C) Nuclear run-on assays for mda-5. Nuclei were prepared from HO-1 melanoma cells treated with the indicated reagents for 4 hours. Blots were prepared and hybridized as described in Materials and Methods. gapdh=glyceraldehyde-3-phosphate dehydrogenase (D) PKC inhibitors in mda-5 expression. RNA samples were extracted from HO-1 melanoma cells pretreated with 50 nM staurosporine or 0.2 μM Ro31-8220 (Calbiochem) for 30 min and treated with the indicated reagents for 8 h. RNA sample preparation and Northern hybridization were performed as described in Materials and Methods. -
FIG. 6 (A-B). Protein expression of mda-5 and intracellular localization. (A) Protein expression from mda-5 cDNA after transient transfection. Protein extracts were prepared from 293 cells transiently transfected with the indicated expression vector and resolved in 9% SDS/PAGE. Western blot analysis was performed with specified antibodies. ctl=control. (B) Intracellular localization of mda-5 protein. Transiently transfected 293 cells on cover slips with the indicated fusion protein constructs were mounted and photographed using fluorescent confocal microscopy (x400). -
FIG. 7 (A-B). Effect of ectopic expression of mda-5 on HO-1 cells. Cells were transfected with the indicated expression vector, replated 2 days later, and selected with G418. (A) Representative colony-forming assays. G418-resistant colonies transfected with the indicated expression vectors are shown. Ctl, control; AS, antisense. (B) Quantitation of the effect of ectopic expression of mda-5 on colony formation. Giemsa-stained G418-resistant colonies containing more than =50 cells were counted. The results are the mean±standard error from three independent transfections (three plates for each transfection) with two different plasmid batches. -
FIG. 8 (A-D). ATPase activity of MDA-5. (A) Electrophoretogram of purified proteins. GST and GST-MDA-5 were resolved on 9% SDS/PAGE and stained with Coomassie brilliant blue. (B) Effect of divalent metal ions and RNA concentration on MDA-5 ATPase activity. ATPase activity assay was performed with variable poly(I):poly(C) concentrations (0.038, 0.375, 3.75, 37.5, and 375 ng/μl). MnCl2 (3 mM,□) substituted for MgCl2 (3 mM, ♦). The results were quantitated by Phosphorlmager. The data shown are the mean±SD from two experiments. Specific activity is nmol/min/μg of protein. (C) Lineweaver-Burk plot of the effect of [ATP] on MDA-5 ATPase activity. ATPase activity was measured with various ATP concentrations (15.6, 31.3, 62.5, 125, 250, and 500 μM) for 20 min in a 37° C. air incubator and quantitated by PhosphorImager. The result shown is the mean±SD from three independent experiments. (D) Autoradiogram of MDA-5 ATPase assay with various RNA species. The indicated types of RNA (20 ng/μl) were added in standard reaction mixture, and the results presented were obtained by exposing a TLC plate to Kodak X-Omat film. D. W., distilled water. -
FIG. 9 . Nucleic acid sequence of mda-5p (SEQ ID NO:4). -
FIG. 10 . Amino acid sequence of protein encoded by mda-5p (SEQ ID NO:7). -
FIG. 11 . Nucleic acid sequence encoding an MDA-5 protein (SEQ ID NO:8). -
FIG. 12 . Amino acid sequence (SEQ ID NO:9) of MDA-5 protein encoded by SEQ ID NO:8. - For purposes of clarity, and not by way of limitation, the detailed description is divided into the following subsections:
- MDA-5 related molecules;
- measuring ATPase activity;
- (iii) use of MDA-5 activity as an antiviral agent; and
- (iv) use of MDA-5 activity as an antiproliferative agent.
- A “mda-5 nucleic acid” according to the invention is a nucleic acid which comprises (i) the nucleic acid sequence as set forth in
FIG. 1 (SEQ ID NO:1), or (ii) a nucleic acid which encodes a protein having an amino acid sequence as set forth inFIG. 2 (SEQ ID NO:2); or (iii) a nucleic acid which hybridizes to a nucleic acid molecule having the sequence set forth inFIG. 1 (SEQ ID NO:1) under stringent conditions; and/or (iv) a nucleic acid which is at least 90 percent homologous to a nucleic acid molecule having a sequence as set forth inFIG. 1 (SEQ ID NO:1), as determined by a standard homology-assessing software program such as BLAST. - For example, the following would be an example of stringent hybridization conditions (which may include wash conditions). Maximum hybridization specificity for DNA samples immobilized on nitrocellulose filters may be achieved through the use of repeated washings under conditions of high stringency, such as when the washings are done in a solution comprising 0.1-0.2×SSC (15-30 mM NaCl, 1.5-3 mM sodium citrate, pH 7.0) and 0.1% SDS (sodium dodecylsulfate) at temperatures of 65-68° C. or greater (Current Protocols in Molecular Biology, Volume I. Ausubel et al., eds. John Wiley:New York N.Y., pp. 2.10.1-2.10.16. 1989 with annual updating). For DNA samples immobilized on nylon filters, a stringent hybridization washing solution may comprise 40 mM NaPO4, pH 7.2, 1-2% SDS and 1 mM EDTA. Again, a washing temperature of at least 65-68° C. is recommended, but the optimal temperature required for a truly stringent wash will depend on the length of the nucleic acid probe, its GC content, the concentration of monovalent cations and the percentage of formamide, if any, that is contained in the hybridization solution (Current Protocols in Molecular Biology, Volume I. Ausubel et al., eds. John Wiley:New York N.Y., pp. 2.10.1-2.10.16. 1989 with annual updating).
- The term “mda-5 nucleic acid” can refer to a cDNA sequence (for example, SEQ ID NO:1), to a genomic DNA sequence, or to an RNA molecule (including an antisense RNA molecule). A mda-5 nucleic acid may be comprised in a vector molecule, for example a virus (which may be a defective or non-defective virus) or a plasmid, phage, cosmid, etc. Additional elements to aid in replication and/or expression may be further comprised in the vector. A mda-5 nucleic acid may, for example, be operably linked to a promoter element which may be a mda-5 promoter or a heterologous promoter. A mda-5 nucleic acid may be of human or non-human species origin.
- The term “mda-5 nucleic acid” further encompasses a variant of the mda-5 nucleic acid having SEQ ID NO:1; this variant is named mda-5p and contains an additional 202 bp attached to the 3′ end of mda-5. The sequence of mda-5p is set forth in
FIG. 9 (SEQ ID NO:4). Yet another variant sequence for an mda-5 nucleic acid is set forth inFIG. 11 (SEQ ID NO:8). - A MDA-5 protein according to the invention is a protein which comprises (i) a protein having the amino acid sequence set forth in
FIG. 2 (SEQ ID NO:2); (ii) a protein having the amino acid sequence set forth inFIG. 10 (SEQ ID NO:7): (iii) a protein having the amino acid sequence set forth inFIG. 12 (SEQ ID NO:9) or (ii) a protein encoded by a nucleic acid which hybridizes to a nucleic acid molecule having a sequence as set forth inFIG. 1 (SEQ ID NO:1) under stringent conditions; and/or (iii) a protein which is at least 90 percent homologous to a protein having an amino acid sequence as set forth inFIG. 2 (SEQ ID NO:2) as determined by a standard homology-assessing software program such as BLAST. A MDA-5 protein may be of human or non-human species origin. - The present invention further provides for antibody molecules which specifically bind to a MDA-5 protein, which may be monoclonal antibodies, polyclonal antibodies, single chain antibodies, or fragments thereof, generated according to methods known in the art.
- A “mda-5 promoter” is a nucleic acid which comprises (i) a nucleic acid comprising the sequence set forth in
FIG. 3 (SEQ ID NO:3); or (ii) a nucleic acid which hybridizes to a nucleic acid having the sequence set forth inFIG. 3 (SEQ ID NO:3) under stringent conditions; and/or (iii) a nucleic acid which is at least 90 percent homologous to a nucleic acid having a sequence as set forth inFIG. 3 (SEQ ID NO:3), as determined by a standard homology-assessing software program such as BLAST. A mda-5 promoter of the invention may be comprised in a vector molecule, such as a virus (defective or non-defective) or plasmid, or phage, or cosmid vector, and/or may be operably linked to a gene of interest. Suitable genes of interest include, but are not limited to, a mda-5 nucleic acid, or a protein which binds to a MDA-5 protein, or a tumor suppressor gene such as (but not limited to) p21, the retinoblastoma tumor suppressor gene, or p53, or a reporter gene, for example, but not limited to, luciferase or beta glucuronidase. - ATPase activity may be measured using any method known in the art. In a preferred specific non-limiting embodiment of the invention, ATPase may be measured using the method set forth in the working example below, as follows.
- An ATPase assay may be performed in a 10-μl reaction mixture containing 50 mM Mops, pH 6.5, 3 mM MgCl2, 2 mM DTT, 0.5 mM ATP, 5 μCi (1 Ci=37 GBq) of [γ-32P]ATP (6,000 Ci/mmol; Amersham Pharmacia), DNA (sonicated salmon sperm) or RNA, and test protein (0.2 μg) in a 37° C. air incubator. Poly(I):poly(C) (Amersham Pharmacia) or other RNA which has been reextracted with acid phenol/chloroform and precipitated may be used as a substrate for the reaction; for example, variable poly(I):poly(C) concentrations (0.038, 0.375, 3.75, 37.5, and 375 ng/μl) may be used. The results may be quantitated by PhosphorImager. The reaction may be initiated by addition of the ATP mixture and the dissociated Pi may be resolved in polyethylene imine cellulose TLC plates as described (Wagner et al., 1998; EMBO J. 17:2926-2937).
- The present invention provides for methods of protecting against or limiting viral infection in a subject comprising administering, to the subject, an agent which increases the level of MDA-5 protein activity in the subject. “Protecting against contracting a viral infection” does not require that there be absolute protection; for example, substantially decreasing the likelihood of infection, for example reducing the risk of infection, with exposure, at least 2-fold, is considered protection. “Limiting viral infection”, as defined herein, refers to any one or more of decreasing the number of cells infected by a virus within a subject or among several subjects; decreasing the cytopathic effect caused by a virus, decreasing the amount of viral replication, decreasing the clinical severity of a viral infection, and/or decreasing the period of time that a subject suffers from a viral infection. “Increasing the level of MDA-5 protein activity in the subject” encompasses increasing the level of MDA-5 protein activity in at least some but not necessarily all cells, tissues, and/or fluids of the subject. The level of MDA-5 protein activity may be measured directly or indirectly, for example, but not by way of limitation, by measuring the amount of MDA-5 protein, the amount of ATPase activity, and/or the amount of MDA-5 encoding mRNA.
- In a more specific, non-limiting embodiment, the present invention provides for a method of protecting against or limiting viral infection in a subject comprising administering, to the subject, a therapeutically effective amount of an agent which increases MDA-5 protein-mediated RNA degradation in the subject.
- In another non-limiting embodiment, the present invention provides for methods of protecting against or limiting viral infection in a subject comprising administering, to the subject, a therapeutically effective amount of an agent which increases ATPase activity in the subject.
- Examples of agents which may be used to increase the level of MDA-5 protein, or MDA-5 protein-mediated RNA degradation, or ATPase activity in a subject include, but are not limited to, (i) MDA-5 proteins; (ii) mda-5 nucleic acids, in expressible form, which encode MDA-5 proteins; (iii) agents which increase the activity of an mda-5 promoter or that stabilize MDA-5 encoding mRNA; (iv) agents which increase the RNA degradation activity of MDA-5 protein; and (v) agents which increase ATPase activity of MDA-5 protein.
- As non-limiting examples within each of these categories, consider the following:
- A therapeutic amount of MDA-5 protein may be administered to a subject by any suitable route, including intravenously, intramuscularly, orally, or by inhalation, so as to supply cells which are infected or at risk of being infected with the protein. The MDA-5 protein may be comprised in a vehicle which aids cellular uptake and/or inhibits protein degradation, for example, in liposomes or microspheres. As a specific non-limiting embodiment, an effective amount of MDA-5 protein may be administered to a subject who has been or may be in contact with a virus spread by the respiratory route in the form of an inhaled aerosol spray.
- A mda-5 nucleic acid may be administered in expressible form, for example, in the form of “naked DNA” or comprised in a vector, for example a viral vector. In particular non-limiting embodiments the virus may be an adenovirus, such as, for example, a replication-defective adenovirus. The mda-5 nucleic acid may be operably linked to a suitable promoter, which may be an mda-5 promoter or a heterologous promoter, such as the cytomegalovirus immediate early promoter, the Rous sarcoma virus long terminal repeat promoter, the human elongation factor −1α promoter, the human ubiquitin c promoter, etc. It may be desirable, in certain embodiments of the invention, to use an inducible promoter. Non-limiting examples of inducible promoters include the murine mammary tumor virus promoter (inducible with dexamethasone); commercially available tetracycline-responsive or ecdysone-inducible promoters, etc. As a specific non-limiting embodiment, an effective amount of an mda-5 nucleic acid, operably linked to a promoter sequence, comprised in a viral vector such as a replication defective adenovirus vector, may be administered to a subject who has been or may be in contact with a virus spread by the respiratory route in the form of an inhaled aerosol spray. For example, the amount of virus administered may be 109-1013 plaque forming units.
- In further embodiments of the invention, an effective amount of a second agent may be administered to the subject before, during, or after administration of MDA-5 protein or mda-5 nucleic acid. The second agent is defined as a facilitator of MDA-5 activity. Examples include, but are not limited to, interferon alpha, interferon beta, interferon gamma, poly(I)(C) and tumor necrosis factor alpha. In additional embodiments, a third agent which promotes mda-5 activity may be additionally administered; for example, but not by way of limitation, if one of the above interferons is used as second agent, another one of these interferons may be used as third agent, or mezerein may be used.
- In still further embodiments of the invention, whether or not a second and/or third agent is used, an effective amount of an antiviral agent is administered to improve the net antiviral defense. The amount of antiviral activity achieved is greater that the amount associated with the antiviral agent used without an mda-5 related molecule. Examples of antiviral agents include, but are not limited to, (i) amantadine, rimantidine, and sialic acid analogues such as zanamivir or other inhibitors of influenza sialidase for the specific inhibition of influenza viruses; (ii) Aayclovir (Zovirax), ganciclovir, valacyclovir (Valtrex), lamivudine (3TC; Epivir) or other nucleoside analogs such as vidarabine for the treatment of herpesvirus infections (HSV-1, HSV-2, VZV (chicken pox), EBV and CMV); (iii) foscamet (Foscavir), a pyrophosphate analog, may be useful in the treatment of the above-mentioned herpesviruses, and also may useful in the treatment of retroviruses including HIV-1; (iv) zidovudine (Retrovir or AZT), didanosine, zalcitabine and related purine analogues such as ribavirin, which are inhibitors of viral reverse transcriptase, for the treatment of retroviruses including HIV-1 (ribavirin is also useful in the treatment of infections caused by arenaviruses (e.g. Lassa fever) or bunyaviruses (e.g. Hantavirus), respiratory syncytial virus (RSV) and in the treatment of Hepatitis C; the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune) may also be useful in the treatment of HIV-1); (v) indinavir (Crixivan), saquinavir (Fortovase) and other HIV protease inhibitors for the treatment of retroviruses including HIV-1; (vi) monoclonal antibody inhibitors of ICAM-1 for the treatment of rhinoviruses, the most common cause of colds; and (vii) zintevir, an HIV integrase inhibitor, for the treatment of HIV-1.
- Many of the above-mentioned drugs can be used in combination to achieve anti-viral effects that are synergistic over those achieved by single-drug therapy, although the choice of combinations must be judicious.
- In alternative embodiments of the invention, an agent which activates an mda-5 promoter may be used to increase transcription of the endogenous mda-5 gene. Among the examples of such agents are certain second agents, facilitators of MDA-5 activity, described above, such as interferon alpha, interferon beta, interferon gamma, tumor necrosis factor alpha, and poly IC. According to this set of embodiments they are administered without an mda-5 nucleic acid or an MDA-5 protein, although administration of an mda-5 promoter activating agent may be combined with one or more other facilitator of MDA-5 activity which does not act at the transcriptional level, and/or with one or more antiviral agent.
- Further agents which activate an mda-5 promoter may be identified and used according to the invention. The invention provides for an assay for identifying an activator of an mda-5 promoter, comprising (i) preparing a nucleic acid construct having an mda-5 promoter operably linked to a reporter gene (defined herein as a gene having a detectable product) for example, but not limited to, a luciferase gene; (ii) introducing the construct into a cell, such as a eukaryotic cell, for example, but not limited to, an HO-1 cell; (iii) exposing the cell to a test agent; (iv) measuring the amount of reporter gene product produced by a cell exposed to the test agent; and (v) comparing the amount of reporter gene product produced by a cell exposed to the test agent to the amount of reporter gene product produced by a cell containing the mda-5 promoter carrying construct which has not been exposed to the test agent. To provide an adequate control, the cell (generally in a cell culture or organism) exposed to the test agent and the cell not exposed to the test agent should otherwise be maintained under the same or similar conditions. An increase in the level of reporter gene product in a cell exposed to the test agent has a positive correlation with an increase in mda-5 promoter activity.
- In still further embodiments of the invention, a therapeutic amount of an agent which increases the RNA degradation activity of MDA-5 protein may be administered to a subject. The present invention further provides for methods of identifying agents which increase the RNA degradation activity of MDA-5 protein. For example, proteins which form physical associations with MDA-5 may be identified, for example, by a yeast two-hybrid assay, or by computerized analysis which predicts interactions between proteins. After identifying a protein which associates with MDA-5, the ability of the identified protein to degrade RNA either alone or in combination with MDA-5 may be tested.
- The present invention further provides for the administration of agents which increase ATPase activity, for example, agents which increase the ATPase activity of MDA-5. The present invention provides for assays for identifying such agents, which comprise combining, in an ATPase assay, MDA-5 protein and a test agent, measuring the ATPase activity of MDA-5 plus test agent, and comparing the resulting ATPase activity to the ATPase activity of the same amount of MDA-5 in the absence of the test agent.
- Examples of infections which may be treated by the foregoing methods are those caused by 1) picomaviruses, a family of viruses that includes polioviruses, Coxsackie viruses, rhinoviruses, enteroviruses, and hepatitis A virus, which can cause poliomyelitus, meningitis, and hepatitis (hepatitis A) in humans, 2) caliciviruses, a family of viruses that include the mild gastroeneteritis-inducing Norwalk group of viruses, 3) astroviruses, which can cause severe gastroenteritis, 4) togaviruses, a family of viruses that includes the alphaviruses, the cause of polyarthritis and a variety of encephalitidies including Eastern and Western equine encephalitis, and rubiviruses, the cause of rubella (German measles), 5) flaviviruses, a family of viruses including flaviviruses, pestiviruses and hepatitis C virus, which can cause St. Louis and West Nile encephalitis among others, tick borne encephalitis, Dengue fever, yellow fever, hepatitis (hepatitis C), and some types of hemorrhagic fevers, 6) coronaviruses, a family of viruses including the coronaviruses, a cause of colds in humans and feline infectious peritonitis in cats, and the toroviruses, 7) arteriviruses, 8) paramyxoviruses, a family of viruses including paramyxoviruses, rubulaviruses, morbilliviruses and pneumonoviruses, which can cause measles and mumps, 9) rhabdoviruses, a family of viruses including rhabdoviruses, vesciculoviruses, lyssaviruses, ephemeroviruses, cytorhabdoviruses and nucleorhabdoviruses, which can cause vescicular stomatitis and rabies among other diseases, 10) filoviruses, notorious as the cause of Ebola and related hemorrhagic fevers, 11) orthomyxoviruses, a family of viruses including influenza A, B and C viruses, major causative agents of influenza infections, 12) bunyaviruses, a family of viruses including bunyaviruses, phleboviruses, nairoviruses, hantaviruses and tospoviruses, viruses associated with the hemorrhagic Hanta fever, encephalitis, and Rift Valley fever, 13) arenaviridae, the cause of Lassa fever and hemorrhagic fevers such as Bolivian, Argentinian or Venezualan hemorrhagic fevers, 14) reoviruses, a family of viruses including orthoreoviruses, responsible for a host of respiratory and enteric infections, orbiviruses, responsible for Colorado tick fever, rotaviruses, a major cause of morbidity stemming from persistent diarrhea in the developing world, coltiviruses, aquareoviruses, cypoviruses, phytoreoviruses, fijiviruses and orzyaviruses 15) bimaviruses, a family of viruses including aquabimaviruses, avibirnaviruses and entomobirnaviruses, 16) retroviruses, a family of viruses containing lentiviruses such as HIV-1 and -2, the causative agent in AIDS, spumaviruses and a range of retroviruses including oncogenic viruses such as the leukemia-inducing HTLV family of viruses and type A, B, C or D retroviruses, 17) hepadnaviruses, a family of viruses including orthohepadnaviruses and avihepadnaviruses, the cause of hepatitis B, 18) circoviruses, 19) parvoviruses, a family of viruses including the chordoparvovirus and entomoparvovirus subfamily comprising erythroviruses, dependoviruses, entomoparvoviruses, densoviruses, iteraviruses and contraviruses, 20) papovaviruses, a family of viruses including papillomaviruses, the cause of warts and some cancers of the cervix and other gential regions, and polyomaviruses, the cause of progressive multifocal leukoencephalopathy and some human malignancies, 21) adenoviruses, a family of viruses including mastadenoviruses and aviadenoviruses, which can cause flu-like respiratory infections in humans, 22) herpesviruses, a family of viruses including the alphaherpesvirus, betaherpesvirus, and gammaherpesvirus subfamilies comprising simplexviruses, varicelloviruses, cytomegaloviruses, muromegaloviruses, roseoloviruses, lymphocryptoviruses and rhadinoviruses, the cause of chicken pox, recurring infections of the oral cavity or the genital tract, mononucleosis and some human malignancies including Burkitt's lymphoma and Hodgkin's disease, 23) poxviruses, a family of viruses including the chordopoxvirus and entemopoxvirus subfamilies comprising orthopoxviruses, the source of smallpox infection, parapoxviruses, avipoxviruses, capripoxviruses, lepropoxviruses, suipoxviruses, molluscipoxviruses, yatapoxviruses, and entomopoxviruses A, B and C, 23) unnamed viruses of the iridovirus family and those causing African Swine Fever, and 24) unclassified human and animal viruses including Borna Disease virus, hepatitis E and X viruses and unclassified arboviruses.
- In further embodiments, where a virus produces a helicase, providing increased levels of MDA-5 by one of the foregoing methods may be used to compete with the viral helicase, which would be desirable where this competition would result in inhibition of the viral helicase and have a negative effect on viral replication and/or pathogenesis. Such negative competition would occur, for example, where the viral helicase has greater ATPase activity relative to MDA-5, and/or where the viral helicase has a different binding affinity for target RNA relative to MDA-5. Such characteristics may be evaluated using standard laboratory techniques. Examples of viruses which encode helicase molecules are poxviruses such as vaccinia, alphaviruses such as Semliki Forest virus (SFV), flaviviruses such as hepatitis C virus (HCV), reoviruses such as human rotaviruses A and B, and picomaviruses such as polio virus, among others.
- The present invention provides for methods of inhibiting cell proliferation and/or promoting apoptosis of a cell population or in a subject comprising administering, to the cell population or subject, an agent which increases the level of MDA-5 protein activity in the subject. Inhibiting cell proliferation and/or promoting apoptosis means decreasing the increase in the number of cells in a population over a time interval, relative to a control population in which the level of MDA-5 protein has not been increased over the same length of time, by at least about 20 percent. “Increasing the level of MDA-5 protein in the subject” encompasses increasing the level of MDA-5 protein in at least some but not necessarily all cells, tissues, and/or fluids of the subject.
- In related embodiments, the present invention provides for methods of inhibiting tumor growth in a subject comprising administering, to the subject, an effective amount of an agent which increases the level of MDA-5 protein activity in the subject.
- Examples of agents which may be used to increase the level of MDA-5 protein activity include, but are not limited to, (i) MDA-5 proteins; (ii) mda-5 nucleic acids, in expressible form, which encode MDA-5 proteins; (iii) agents which increase the activity of an mda-5 promoter or that stabilize MDA-5 encoding mRNA; and (iv) agents which increase the RNA degradation activity of MDA-5 protein. These agents have been described in the foregoing section.
- In particular embodiments, it may be desirable to co-administer an effective amount of an interferon, such as interferon alpha, interferon beta, or interferon gamma.
- The foregoing agents may be administered in conjunction with one or more additional anti-neoplastic agent, including, but not limited to, a chemotherapeutic agent, immunotherapy, radiation therapy, and the like.
- Examples of malignancy which may be treated according to the present invention include, but are not limited to, melanoma, glioblastoma multiforme, neuroblastoma, astrocytoma, osteosarcoma, breast cancer, cervical cancer, colon cancer, lung cancer, Kaposi's sarcoma, hairy cell leukemia, nasopharynx cancer, ovarian cancer, and prostate cancer.
- The present invention also provides for the use of MDA-5 to sensitize a cell to the growth inhibitory and/or apoptosis-promoting effect(s) of a protein kinase C inhibitor (including, but not limited to, mezerein). According to such embodiments, one of the foregoing agents which increase MDA-5 protein activity may be administered prior to, coincident with, or after administering a protein kinase C inhibitor. Such methodology may also be used to eliminate virus-infected cells. Moreover, new inhibitors of protein kinase C may be identified by their ability to inhibit cell proliferation/promote apoptosis in the context of increased MDA-5 protein activity.
- In still further embodiments, a mda-5 promoter may be used to deliver and express genes targeting virally infected cells for destruction. For example, the mda-5 promoter could be used in a virus comprising a first cancer-inhibitory gene (e.g., p53, mda-7) operably linked to a promoter selectively active in cancer cells (e.g., PEG-3), and further comprising a second cancer-inhibitory gene (e.g., IL-2, interferon gamma, interleukin 12) operably linked to a mda-5 promoter. Such a virus would have cancer targeted specificity (due to the first promoter) and IFN or similar inducing agent induction potential (due to the mda-5 promoter, thereby augmenting the killing of cancer cells.
- Cell Cultures. HO-1 human melanoma cells and 293 cells were grown as described (Fisher et al., 1985, J. Interferon Res 5:11-22). Sf9 cells were cultured in TNM-FH medium (Mediatech Laboratories, Cody, N.Y.) supplemented with 10% FBS and penicillin/streptomycin (100 units/100 μg/ml) at 27° C. in a humidified incubator.
- Cloning and Sequencing of mda-5. A partial mda-5 cDNA (3′, 1.8 kb) was cloned by screening a human placental cDNA library (CLONTECH; Ausubel et al., 1992. Short Protocols in Molecular Biology. Wiley:New York). The remaining 5′ region of the mda-5 cDNA (1.5 kb) was obtained by using a modified rapid amplification of cDNA ends approach. This approach involved an anchor primer instead of poly(A) or (G) tailing designed to anneal to the 5′ end of the mda-5 cDNA, followed by second-strand synthesis and subsequent PCR using an mda-5-specific reverse transcription primer to generate a full-length mda-5 cDNA.
- Northern Blot Analyses and Nuclear Run-On Assays. RNA preparation and Northern blot hybridization were performed as described (Ausubel et al., 1992. Short Protocols in Molecular Biology. Wiley:New York). Northern blots were probed with a 32P-labeled 2.5-kb EcoRI fragment of mda-5 cDNA and a 0.7-kb glyceraldehyde-3-phosphate dehydrogenase fragment. Nuclear run-on assays were performed as described (Ausubel et al., 1992. Short Protocols in Molecular Biology. Wiley:New York). Probes used for nuclear run-on assays included: mda-5 5′, 9-837 bp; mda-5 3′, 2,531-3,365 bp; and a glyceraldehyde-3-phosphate dehydrogenase fragment (0.7 kb). Autoradiograms were quantitated by densitometry using a Molecular Dynamics densitometer.
- mda-5 Expression Vectors. A hemagglutinin (HA)-tagged mda-5 fragment was obtained by reverse transcription-PCR, using
primers 5′-GCCACCATGTACCCATACGACGTCCCAGACTACGCTATGTCGAATGGGTATT CCACAGACG-3′ (SEQ ID NO:5) and 5′-TCACTAATCCTCATCACTAAATAAACAGC-3′ (SEQ ID NO.:10), and was cloned into the EcoRV site of pcDEF3 with expression regulated by the EF-1α promoter. An antisense mda-5 expression vector was constructed by cloning the EagI/SpeI mda-5 genomic DNA (3.8-kbp) fragment from a bacterial artificial chromosome clone into the SpeI/NotI site of pcDEF3. The genomic DNA fragment consists of the first exon and part of the first intron. A green fluorescent protein (GFP)-mda-5 fusion expression vector was constructed by ligation of an mda-5 cDNA product, derived by reverse transcription-PCR using theprimers 5′-ATGTCGAATGGGTATTCCACAGACG-3′ (SEQ ID NO:6) and 5′-TTTTTTTTTTTTCAGAGTAAAACAATC-3′ (SEQ ID NO.:11), into the SmaI site of pEGFP-C2 (CLONTECH). - Western Blot Analysis and Fluorescent Confocal Microscopy. Transient transfections were performed by using SuperFect (Qiagen, Chatsworth, Calif.) as described in the manufacturer's protocol. Ten micrograms of supercoiled plasmid DNA (pcDEF3, pcDEF3/HA-mda-5, pEGFP-C2, and pEGFP-C2/mda-5) were transfected into ≈70% confluent 293 cells and plated 1 day before transfection in a 10-cm plate, and cells were harvested 2 days after transfection. Protein sample preparation and Western blotting were performed as described in Jiang et al., 1995, Oncogene 11:2477-2486. MDA-5 fusion proteins were probed with either α-HA antibody (Roche Diagnostics) or α-GFP antibody (CLONTECH) and with horseradish peroxidase-conjugated anti-Mouse IgG (Sigma) and detected by ECL (Amersham Pharmacia). For intracellular localization, 105 cells per well were seeded in 6-well plates containing a cover glass and transfected with the indicated plasmids (pEGFP-C2 and pEGFP-C2/mda-5, 2.5 μg per well). For fluorescence microscopy, the cover glass containing transfected cells was washed with PBS and mounted onto a glass slide with mounting medium. The cells were observed by fluorescent confocal microscopy.
- Colony-Forming Assays. HO-1 melanoma cells were plated at 8×105 in a 6-
cm dish 1 day before transfection with 5 μg of supercoiled plasmid DNA. Two days after transfection, cells were trypsinized and replated at 105 cells per 6-cm dish with complete medium containing 750 μg of G418/ml. The G418-containing medium was replaced once a week for 3 weeks. Cells were fixed with methanol (−20° C.) and stained with Giemsa (Sigma). Colonies with more than 50 cells were enumerated. - Purification of Glutathione 5-Transferase (GST)-MDA-S Fusion Protein. A baculovirus transfer vector of GST-MDA-5 was constructed by ligation of the XhoI-BamHI mda-5 fragment from the pEGFP-C2/mda-5 and XhoI BgIII sites of pAcGHLT-C (PharMingen). The transfer vectors of GST only and GST-MDA-5 fusion (5 μg each) were transfected into Sf9 cells, and recombinant virus producer cells were selected as described by the manufacturer (PharMingen). GST and GST-MDA-5 fusion proteins were expressed and purified by affinity chromatography with glutathione-
Sepharose 413 as described by the manufacturer (PharMingen). - ATPase Assay. ATPase assays were performed in a 10-μl reaction mixture containing 50 mM Mops, pH 6.5, 3 mM MgCl2, 2 mM DTT, 0.5 mM ATP, 5 μCi (1 Ci=37 GBq) of [(−32P]ATP (6,000 Ci/mmol; Amersham Pharmacia), DNA (sonicated salmon sperm) or RNA, and protein (0.2 μg) in a 37° C. air incubator. Poly(I)·poly(C) (Amersham Pharmacia) and other RNA samples were reextracted with acid phenol /chloroform and precipitated. Specific assay conditions are described in the figure legends. The reaction was started by addition of the ATP mixture and the dissociated Pi was resolved in polyethylene imine cellulose TLC plates as described (Wagner et al., 1998; EMBO J. 17:2926-2937).
- IFN-β+MEZ Induces Terminal Differentiation in HO-1 Cells. Treatment of HO-1 melanoma cells with IFN-β (2,000 units/ml) plus MEZ (10 ng/ml) results in rapid and irreversible growth suppression, induction of dendrite-like processes, and enhanced melanogenesis (Fisher P B et al., 1985, J. Interferon Res 5:11-22; Jiang H et al., 1993, Mol Cell Different 1:41-66). This combination treatment also results in a subset of detached cells that display Ao DNA content by fluorescence-activated cell sorter analysis, which is indicative of apoptosis. These floating cells are apparent first at 48 h. In contrast, treatment with either agent alone inhibits growth and melanogenesis in a reversible manner, and treated cells do not terminally differentiate or undergo apoptosis. In this context, induction of terminal differentiation in HO-1 cells by the combination treatment would be anticipated to involve the induction of genes that are relevant to the mode of action of the individual inducing agents, i.e. IFN-β and MEZ, related to both reversible and terminal differentiation, and associated with apoptosis (Jiang and Fisher, 1993, Mol Cell Different 1:285-299; Jiang H et al., 1993, Mol Cell Different 1:41-66; Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-156).
- Sequence Analysis of mda-5. The cloned mda-5 cDNA [3,365 bp, excluding the poly(A) tail] contains a 1,025-amino acid-encoding ORF (nucleotides 169-3,246) with a predicted molecular mass of 116.7 kDa and a pI of 5.44. The first AUG at position 169 likely represents a genuine start codon caused by the presence of an in-frame stop codon at nucleotide 159 and an A−3 Kozak consensus sequence (AXXaugG; Kozak M, 1996, Mamm Genome 7:563-574). A polyadenylation signal (AATAAA) is located 23 by upstream of the poly(A) tail. In vitro translation of the mda-5 cDNA resulted in a protein with apparent molecular mass of 120 kDa and additional smaller bands, most likely truncated translation products of MDA-5.
- Sequence analysis of the MDA-5 protein in the Prosite database identities two conserved domains, a DExH/D RNA helicase domain and a CARD. No nuclear localization signal or RNA binding domains were found in this protein. The C-terminal 102 amino acids (nucleotides 722-823) of MDA-5 show homology to the RNA helicase C-terminal conserved domain, a signature motif of helicase superfamily II, which consists of three subfamilies (DEAD, DEAH, and DEXH) based on their ATPase B motif (Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-296; Jankowsky and Jankowsky, 2000, Nucleic Acids Res 28:333-334). At least eight of nine motifs are well conserved among DExH group helicases (Jankowsky and Jankowsky, 2000, Nucleic Acids Res 28:333-334). These eight DExH group helicase motifs display high conservation but show some divergence in MDA-5 (numbered in
FIG. 4 ). The distance between consensus motifs, which also are well conserved in the DEAD group helicases (Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-296), are extended further in MDA-5 (FIG. 4 ). In these contexts, MDA-5 seems to be a divergent form of DExH RNA helicase. - The ProDom database recognizes 10 cloned or hypothetical proteins closely related in their helicase domain to MDA-5 (dating back to early prokaryotes: Methanobacterium thermoautotrophicum, 027466; Schizosaccharomyces pombe, Q09884; Caenorhabditis elegans, Q17545, Q44165, and P34529; Arabidopsis thaliana, Q9SP32; Sus scrofa, RHIV-1; and Homo sapiens, RIG-1, Q9HAM6, and Q9UPY3). Proteins except RIG-7 (Sun Y W, 1995, In Sanghai Institute of Hematology. Rui-Jin Hospital (Sanghai Second Medical University, Sanghai, China)), RHIV-1 (Zhang et al., 2000, Microb Pathog 28:267-278), and Q9SP32 (Jacobsen et al., 1999, Development 126:5231-5243) contain hypothetical ORFs deduced from genomic sequence analysis of diverse species. CLUSTALW sequence alignment of representatives of these proteins (MDA-5, RIG-1, Q9HAM6, RHIV-1, P34529, Q9SP32, and Q09884) revealed that the DExH helicase motifs found in MDA-5 and 10 additional motifs/residues are well conserved within this group of proteins (
FIG. 4 ). The greatest sequence homology to the MDA-5 helicase domain was observed with Q9HAM6, a hypothetical ORF from the human genome. The conserved pattern of helicase motifs among these molecules possibly signifies a newly identified subgroup of DExH RNA helicases. Among them, MDA-5 is the first protein with documented RNA-dependent ATPase activity (FIG. 8 ). - RNA helicases impinge on many biological phenomena including cell differentiation, proliferation, development, and viral life cycle (Lüking et al., 1998, Crit Rev Biochem Mol Biol 33(4):259-296; Jankowsky and Jankowsky, 2000, Nucleic Acids Res 28:333-334). Although RNA helicases are well conserved in their ATPase and helicase motifs, a direct correlation between sequence motifs and function is not clear-cut. In this context, it is not possible to deduce the potential functions) of MDA-5 based on its primary structure. However, it is worth noting that four of the molecules (Q93P32, Q09884, P34529, and Q9UPY3) of this group contain an RNase III motif as well as an RNA helicase domain. RNase III is an enzyme targeting double-stranded RNA and is involved in gene silencing by RNA interference (Bernstein et al., 2001, Nature 409(6818):363-6). Thus, it is conceivable that MDA-5, through its ATP-dependent unwinding of RNA, most likely functions to promote message degradation by specific types of RNase.
- The biological context of expression and function of the four cloned proteins (MDA-5, RIG-1, RHIV-1, and Q9SP32) are strikingly similar. RIG-1 is expressed during all-trans retinoic acid-induced promyelocytic differentiation (Sun Y W, 1995, In Sanghai Institute of Hematology. Rui-Jin Hospital (Sanghai Second Medical University, Sanghai, China)) and also is induced by IFN-β in HO-1 cells. The expression of RHIV-1 is induced by viral infection suggesting IFN inducibility (Zhang et al., 2000, Microb Pathog 28:267-278). In addition, Q93P32 (also known as CAF) seems to suppress cell division in floral meristems (Jacobsen et al., 1999, Development 126:5231-5243). mda-5 is expressed during differentiation induced by IFN-/3 plus MEZ, which also involves growth inhibition. In this regard, it is possible that the putative helicases of this subgroup may participate in similar biochemical changes associated with growth inhibition and differentiation.
- A distinctive attribute of MDA-5 involves the N-terminal one-third of this molecule. This region of the MDA-5 protein contains a CARD (amino acids 125-174), with significant but relatively low probability (P 0.04). The CARD is a structural motif that consists of amphipathic α-helices and is present in various pro- and antiapoptotic molecules (Hofmann et al., 1997, Trends Biochem Sci 22:155-156). The recruitment of caspase to apoptotic signaling receptor complexes through CARD-CARD interactions has been documented (Chou et al., 1998, Cell 94:171-180). Although the N-
terminal 50 amino acids (125-174) of MDA-5 do not align with other CARD proteins, probably because CARD is a structural motif, secondary structure analysis of amino acids 101-200 of MDA-5 with secondary structural content prediction indicates 83.3% α-helical contents in this area. Based on these considerations, it is likely that the MDA-5 N terminus contains a CARD, and would represent the first RNA-modulating molecule associated with programmed cell death. - mda-5 Expression Analysis. Because mda-5 was cloned in the context of induction of growth arrest and both reversible and terminal differentiation in HO-1 cells, experiments were performed to determine the effect on expression of agents affecting these parameters. Of the agents tested that influence melanocytic differentiation in human melanoma cells (Kang et al., 2001, Gene 267:233-242;
FIG. 5A ) and modulate melanoma growth (Garbe et al., 1993, J. Invest Dermatol 100:239S-244S;FIG. 5B ), only IFNs (α, β, and γ and TNF-α significantly increased steady-state mda-5 transcript levels within 24 h. However, the magnitude of induction by IFN-β was at least 3-fold greater than with IFN-γ, IFN-α, and TNF-α. Induction of DNA damage by exposure to the alkylating agent methyl methanesulfonate or growth in serum-free medium for 24 h did not induce mda-5 expression. Although MEZ treatment for 24 h by itself did not induce mda-5 expression, it augmented mda-5 expression by 1.5-fold when used in combination with IFN-β or IFN-((FIG. 5A ). Although mda-5 is an IFN- and TNF-α-responsive gene, it responds primarily to IFN-β treatment. Because the other differentiation/growth-regulating reagents tested were not effective inducers of mda-5 expression, the primary role of mda-5 in the induction of terminal cell differentiation of HO-1 cells by IFN-β+MEZ seems to be restricted to IFN-β-mediated suppression of cell proliferation and/or induction of apoptosis (Stark et al., 1998, Annu Rev Biochem 67:227-264). - The timing of mda-5 expression was studied also by Northern blotting, indicating induction of mda-5 mRNA by 2 h of treatment with IFN-β or IFN-β+MEZ. The mda-5 message level peaked between 6 and 8 h and remained elevated over a 96-h period. Although MEZ further increased mda-5 message level above that observed with IFN-β alone, it did not affect the timing of mda-5 expression. Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) did not inhibit the induction of mda-5 by IFN-β or IFN-β+MEZ. These results, which correspond with the early onset of mda-5 expression induced by these reagents, provide support for mda-5 being an early response gene induced without prior protein synthesis. They also indicate that mda-5 plays a critical role during an early stage of IFN-induced biological response. The organ-specific expression pattern of mda-5 was determined by hybridization with multiple tissue Northern blots (CLONTECH). Most organs expressed mda-5 at low levels except the brain, testis, and lung, in which expression was barely detectable. Although mda-5 expression was ≈2-fold higher in placenta, pancreas, and spleen than other organs, no organ manifested significantly high enough expression to suggest a correlation between mda-5 expression and specific organ function. Northern blot analysis of mda-5 expression in cancer and normal cell lines of various sources again indicated low basal levels of expression with strong induction by IFN-β.
- Treatment of human skin fibroblasts with IFNs or TNF-α induces and MEZ augments mda-5 expression in a similar manner as in HO-1 cells. These results suggest that induction of mda-5 by these agents may represent a general response of this gene occurring in different cellular contexts. Among the cytokines inducing mda-5 expression, IFN-β is the most potent. Gene expression profiles induced by type I IFNs (a/β), which bind to common receptors and share transcription factors, are quite similar, but the magnitude of differential gene expression and growth-inhibitory effects induced by IFN-β are more profound, as observed with mda-5 induction (Kang et al., 2001, Gene 267:233-242; Stark et al., 1998, Annu Rev Biochem 67:227-264; Garbe et al., 1990, J Invest Dermatol 95:231S-237S). Although differences have been reported in tyk2 requirement and specific coprecipitation of IFNARI with IFN-β but not with IFN-α, the mechanism underlying these differences in signal transduction between type I IFNs is not well understood (Stark et al., 1998, Annu Rev Biochem 67:227-264). IFN-γ and IFN-γ+MEZ induce 3-fold lower levels of mda-5 mRNA than IFN-β and IFN-β+MEZ, but these treatments also directly induce mda-5 expression without prior protein synthesis. It is possible that the mda-5 promoter contains an IFN-γ response sequence such as GAS (Stark et al., 1998, Annu Rev Biochem 67:227-264). Alternatively, the signal generated by IFN-γ may impact on mda-5 expression through shared signaling components with IFN-β but not through IFN-β production. In 3T3-L1 adipocytes, TNF-α activates the Janus kinase/signal transducer/activator of transcription signal transduction (Jak/STAT) pathway, which is stimulated by type I IFNs (Guo et al., 1998, J. Immunol 160:2742-2750). TNF-α may induce mda-5 expression in HO-1 cells by activation of Jak/STAT signals as found in 3T3-L1 cells. Therefore, the Jak/STAT signal transduction pathway seems to be a major contributor to mda-5 expression.
- IFNs were identified initially as molecules that provide immediate protection against viral infection by eliciting an antiviral state in exposed cells (Stark et al., 1998, Annu Rev Biochem 67:227-264). IFN treatment evokes diverse responses depending on the target cell including growth inhibition, changes in differentiation, induction or inhibition of apoptosis, and changes in the expression of immune system modulating genes (Leszczyniecka et al., 2001, Pharmacol Ther 90(2-3):105-56; Stark et al., 1998, Annu Rev Biochem 67:227-264; Grant et al., 1985, Biochem Biophys Res Commun 130:379-388; Greiner et al., 1985, Pharmacol Ther 31:209-236). The highly inducible nature of mda-5 expression by IFNs regardless of cell type, especially IFN-β, the relatively low basal message level in various organs, and the rapid response to IFN treatment strongly suggest that mda-5 plays a critical role in responses that are specific for IFN signaling such as antiviral effect, growth inhibition, and apoptosis but may be less critical during normal physiological processes.
- Although CARD interactions were not reported previously in IFN signaling, IFNs and their biological effectors do sensitize or induce apoptosis in specific cellular contexts, suggesting a link between IFN and apoptotic signaling (Stark et al., 1998, Annu Rev Biochem 67:227-264; Balachandran et al., 2000, J Virol 74:1513-1523). Coincidentally, although not as effective as IFN-13, TNF-∀, an apoptotic cytokine, also induces mda-5 expression in both HO-1 and human fibroblasts (Wallach et al., 1999, Annu Rev Immunol 17:331-367;
FIG. 5B ). Hence, MDA-5 may interact with death molecules through CARD and participate in the IFN- and/or TNF-α-induced apoptotic process by modulating RNA structure. MDA-5 also could have multiple functions with one or more of its potential enzymatic activities predominating, depending on the cellular context and presence of other coeffectors, e.g. CARD-containing proteins. - Nuclear run-on assays of HO-1 cells treated with IFN-β confirmed increases in mda-5 transcription in comparison with undetectable levels of transcription in untreated or MEZ-treated cells (
FIG. 5C ). The combination of IFN-β+MEZ further enhanced the transcription level of mda-5 as compared with IFN-β alone, an observation compatible with effects on steady-state message levels. These findings suggest that MEZ, in the combinatorial treatment protocol, augments mda-5 expression induced by IFN-β at a transcription level. Analysis of mda-5 mRNA stability by using actinomycin D to block transcription revealed that the half-life of the mda-5 transcript was ≈5 h and the decay rate of mda-5 message was indistinguishable between single- and combination-treated cells. These data document that the increased steady-state levels of mda-5 message by IFN-β and IFN-β+MEZ treatment are primarily the result of increased mda-5 transcription. - The ability of IFN-β+MEZ to potentiate mda-5 mRNA levels suggests cooperativity between IFN and MEZ signaling in regulating mda-5 expression. Because MEZ is an activator of PKC, a potential role for PKC in enhancing mda-5 expression after IFN-β+MEZ treatment was tested by pretreatment of HO-1 cells with PKC-specific inhibitors, staurosporine or Ro31-8220 (Tamaoki et al., 1986, Biochem Biophys Res Commun 135:397-402; Morreale et al., 1997, FEBS Lett 417:38-42;
FIG. 5D ). Both reagents abolish the enhanced mda-5 induction by combination treatment. These findings indicate that both IFN and PKC signaling pathways are required for maximal induction of mda-5 expression in HO-1 cells. However, because MEZ does not always augment gene expression induced by IFN-β (e.g. human UBP43; Kang et al., 2001, Gene 267:233-242), crosstalk between PKC and IFN signaling pathways for all up-regulated genes seems unlikely. The higher level of induction seen in combination-treated cells seems to be through direct but independent action on the mda-5 promoter. - Intracellular Localization of MDA-5. A GFP-MDA-5 fusion protein was transiently expressed in 293 cells and Western blot analysis of cell lysates detected a predicted 160-kDa protein (GFP-tagged) in mda-5 cDNA-transfected cells (
FIG. 6A ). Confocal fluorescence microscopy of 293 cells transiently transfected with GFP-MDA-5 fusion protein demonstrated that the protein localizes in the cytoplasm (FIG. 6B ). The cytoplasmic localization of the MDA-5 protein corresponded with the absence of a nuclear localization signal in the MDA-5 protein. No specific localization pattern within the cytoplasm of the GFP-MDA-5 fusion protein was apparent. Cytoplasmic localization of MDA-5 suggests that MDA-5 plays a role in the translation, sequestration of specific mRNAs, or in regulating mRNA stability. - mda-5 Inhibits the Colony-Forming Ability of HO-1 Cells. Treatment of HO-1 cells with 2,000 units/ml of IFN-β for 4 days results in ≈60% growth inhibition versus untreated controls (Fisher et al., 1985, J. Interferon Res 5:11-22; Jiang et al., 1993, Mol Cell Different 1:41-66). Because mda-5 is induced primarily by IFN-β in HO-1 cells, ectopic expression of mda-5 could mimic the effect of IFN-β3 treatment and inhibit growth. To test this possibility, the mda-5 gene was expressed in HO-1 cells by transfection, and colony-forming ability was determined (
FIGS. 7A and B). Expression of the mda-5 construct was confirmed in 293 cells, which are more efficient for transfection than HO-1 cells. Western blot analysis using α-HA antibody showed a protein band corresponding to the predicted size of MDA-5 (=120 kDa) in HA-mda-5-transfected cell lysates (FIG. 6A ). After verifying HA-MDA-5 expression, colony-forming efficiency of HO-1 cells was determined after transfection with parental vector, HA-mda-5 expression vector, or an antisense mda-5 expression vector. The number of G418-resistant HO-1 colonies developing after transfection with the mda-5 expression vector was reduced significantly (≈67%, P<0.05) in comparison with cells transfected with parental vector (FIG. 7B ). In contrast, transfection with the antisense mda-5 expression vector did not effect colony formation significantly, which supports a specific role of mda-5 in regulating the growth of HO-1 cells. Moreover, attempts to obtain stable HO-1 cell clones expressing mda-5 have proven unsuccessful thus far, providing substantiation for a growth-inhibitory effect of mda-5 in these cells. - ATPase Activity of MDA-5. A GST-fusion protein of MDA-5 was purified by glutathione-Sepharose affinity chromatography and the purified GST-MDA-5 migrates as a single protein in SDS-PAGE with an apparent molecular mass of 170 kDa (
FIG. 8A ). GST as a control was expressed and purified in a manner similar to that for GST-MDA-5 (FIG. 8A ). The ATPase activity of the MDA-5 fusion protein was 2-fold more active at pH 6.5 than at pH 7.5 but strictly depended on poly(I)-poly(C) (primarily exists as a double-stranded molecule) at both pH values. Poly(I)·poly(C) has been shown to induce mda-5 in HO-1 and other cancer cells. The requirement of divalent metal ions and effective RNA concentrations for MDA-5 ATPase activity were determined at various poly(I)·poly(C) concentrations by using either Mg2+ or Mn2+ (FIG. 8B ). The presence of Mn2+ shifted the optimal poly(I)·poly(C) concentration for MDA-5 ATPase activity to a higher range. ATPase activity peaked at 3.75 ng of poly(I)-poly(C)/μl with Mg2+ and at 37.5 ng of poly(I)·poly(C)/μl with Mn2+. The specific activity of MDA-5 at optimal conditions was calculated as 1.01±0.22 nmol·min·μg of protein with Mg2+ and 0.80±0.03 nmol·min·μg of protein with Mn2+. These results suggest that Mg2+ is likely to be the preferred ion for MDA-5. Unexpectedly, increasing poly(I)·poly(C) concentrations did not increase MDA-5 ATPase activity. At the highest poly(I)-poly(C) concentration tested, ATPase activity of MDA-5 was reduced to 0.20, ≈0.25-fold of peak activity. Depletion of divalent metal ions by excessive poly(I)·poly(C) provides a possible explanation for this phenomenon. ATPase activity of MDA-5 also was determined at various ATP concentrations, and the calculated Km value for ATP as determined by double reciprocal plot between [ATP] and hydrolyzed Pi fraction was 26 μM (FIG. 8C ). The Km value of MDA-5 for ATP is lower than other well characterized RNA helicases including eIF4A (DEAD helicase, 160 μM; Pause et al., 1993, Mol Cell Biol 13:6789-6798), NPH-11 (DEAH helicase, 1.2 mM) (Gross and Shuman, 1996, J. Virol 70:1706-1713), and hepatitis C virus NS3 protein (DECH helicase, 42 μM without RNA; Kim et al., 1997, J. Virol 71:9400-9409). Based on these results, MDA-5 is strictly an RNA-dependent ATPase, the activity of which may be limited more by the presence of double-stranded RNA than by [ATP]. These results also reinforce the suggestion that MDA-5 is an ATP-dependent RNA helicase. - To identify a potential target of MDA-5, the ATPase activity of MDA-5 was measured in the presence of cellular RNA samples. Of interest, no significant ATPase activity was observed with total, either poly(A) or poly(A)-negative RNA, from IFN-treated HO-1 cells and yeast tRNA (20 ng/μl in
FIG. 8D ; 375 ng/μl). The lack of a stimulatory effect on MDA-5 ATPase activity by cellular RNA may reflect the heterogeneous nature of the cellular RNA populations or the extent of double-stranded RNA. However, although rRNA and tRNA are highly double-stranded and relatively homogeneous in comparison with poly(A) RNA, they did not activate MDA-5 ATPase activity, thereby ruling out these molecules as potential substrates for MDA-5. ATPase activity was apparent also with poly(A, U), which was significantly higher than with poly(I, U), suggesting no specific preference for inosinic acid. - Various publications, including journal articles, electronic documents, patents and patent applications are cited herein, the contents of which are hereby incorporated by reference in their entireties.
Claims (24)
1. A method of protecting a subject against contracting a viral infection comprising administering, to the subject, an effective amount of an agent which increases the level of MDA-5 protein activity in the subject.
2. The method of claim 1 , where the viral infection is caused by a virus which produces a viral helicase.
3. The method of claim 1 , where the viral infection is caused by a virus which does not produce a viral helicase.
4. The method of claim 1 , wherein the agent is a MDA-5 protein.
5. The method of claim 4 , where the MDA-5 protein comprises a protein having an amino acid sequence as set forth in SEQ ID NO:2.
6. The method of claim 2 , wherein the agent is a MDA-5 protein.
7. The method of claim 6 , where the MDA-5 protein comprises a protein having an amino acid sequence as set forth in SEQ ID NO:2.
8. The method of claim 3 , wherein the agent is a MDA-5 protein.
9. The method of claim 8 , where the MDA-5 protein comprises a protein having an amino acid sequence as set forth in SEQ ID NO:2.
10. The method of claim 1 , wherein the agent increases the RNA degradation activity of MDA-5 protein.
11. The method of claim 1 , wherein the agent increases the ATPase activity of MDA-5 protein.
12. The method of claim 1 , further comprising administering, to the subject, an interferon in an amount such that the combined effects of interferon and agent confer protection against viral infection.
13. The method of claim 1 , further comprising administering to the subject an antiviral agent in an amount such that the combined effects of the antiviral agent and the agent confer protection against viral infection.
14. A method of limiting a viral infection in a subject comprising administering, to the subject, an effective amount of an agent which increases the level of MDA-5 protein activity in the subject.
15. The method of claim 14 , where the viral infection is caused by a virus which produces a viral helicase.
16. The method of claim 14 , where the viral infection is caused by a virus which does not produce a viral helicase.
17. The method of claim 14 , wherein the agent is a MDA-5 protein.
18. The method of claim 17 , where the MDA-5 protein comprises a protein having an amino acid sequence as set forth in SEQ ID NO:2.
19. The method of claim 15 , wherein the agent is a MDA-5 protein.
20. The method of claim 19 , where the MDA-5 protein comprises a protein having an amino acid sequence as set forth in SEQ ID NO:2.
21. The method of claim 17 , wherein the agent is a MDA-5 protein.
22. The method of claim 21 , where the MDA-5 protein comprises a protein having an amino acid sequence as set forth in SEQ ID NO:2.
23. The method of claim 14 , wherein the agent increases the RNA degradation activity of MDA-5 protein.
24. The method of claim 14 , wherein the agent increases the ATPase activity of MDA-5 protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/042,922 US20050186211A1 (en) | 2000-02-29 | 2005-01-24 | Use of mda-5 as an antiviral and antiproliferative agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/515,363 US7229822B1 (en) | 2000-02-29 | 2000-02-29 | Melanoma differentation associated gene-5 and vectors and cells containing same |
PCT/US2001/006960 WO2001064707A1 (en) | 2000-02-29 | 2001-02-28 | Melanoma differentiation associated gene - 5 and promoter and uses thereof |
US10/055,475 US20030022855A1 (en) | 2000-02-29 | 2002-01-22 | Use of MDA-5 as an antiviral and antiproliferative agent |
US11/042,922 US20050186211A1 (en) | 2000-02-29 | 2005-01-24 | Use of mda-5 as an antiviral and antiproliferative agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/055,475 Continuation US20030022855A1 (en) | 2000-02-29 | 2002-01-22 | Use of MDA-5 as an antiviral and antiproliferative agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050186211A1 true US20050186211A1 (en) | 2005-08-25 |
Family
ID=24051036
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,363 Expired - Fee Related US7229822B1 (en) | 2000-02-29 | 2000-02-29 | Melanoma differentation associated gene-5 and vectors and cells containing same |
US10/055,475 Abandoned US20030022855A1 (en) | 2000-02-29 | 2002-01-22 | Use of MDA-5 as an antiviral and antiproliferative agent |
US10/228,897 Expired - Fee Related US7220575B2 (en) | 2000-02-29 | 2002-08-26 | Melanoma differentiation associated gene-5 and promoter and uses thereof |
US11/042,922 Abandoned US20050186211A1 (en) | 2000-02-29 | 2005-01-24 | Use of mda-5 as an antiviral and antiproliferative agent |
US11/805,429 Abandoned US20070259372A1 (en) | 2000-02-29 | 2007-05-22 | Melanoma differentiation associated gene - 5 and promoter and uses thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,363 Expired - Fee Related US7229822B1 (en) | 2000-02-29 | 2000-02-29 | Melanoma differentation associated gene-5 and vectors and cells containing same |
US10/055,475 Abandoned US20030022855A1 (en) | 2000-02-29 | 2002-01-22 | Use of MDA-5 as an antiviral and antiproliferative agent |
US10/228,897 Expired - Fee Related US7220575B2 (en) | 2000-02-29 | 2002-08-26 | Melanoma differentiation associated gene-5 and promoter and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/805,429 Abandoned US20070259372A1 (en) | 2000-02-29 | 2007-05-22 | Melanoma differentiation associated gene - 5 and promoter and uses thereof |
Country Status (6)
Country | Link |
---|---|
US (5) | US7229822B1 (en) |
EP (1) | EP1259530A4 (en) |
JP (1) | JP2003531581A (en) |
AU (1) | AU2001247274A1 (en) |
CA (1) | CA2401741A1 (en) |
WO (1) | WO2001064707A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048976A3 (en) * | 2006-10-18 | 2008-11-20 | Us Gov Health & Human Serv | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors |
US20110165600A1 (en) * | 2008-09-01 | 2011-07-07 | Masataka Kuwana | Diagnosis method and diagnosis kit for dermatomyositis |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2808801B1 (en) * | 2000-05-11 | 2004-10-08 | Istac | POLYPEPTIDE RH116 AND ITS FRAGMENTS AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES AND THERAPEUTIC APPLICATIONS |
JP2005073621A (en) * | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | Marker for cerebral tumor and method for diagnosing cerebral tumor |
AU2008343758A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
CN102480967A (en) | 2009-06-26 | 2012-05-30 | 罗马克实验室有限公司 | Compounds and methods for treating influenza |
ES2368963B1 (en) * | 2009-07-04 | 2012-10-10 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | PROCEDURE FOR IDENTIFICATION OF THERAPEUTIC AGENTS AGAINST MELANOMA AND USE OF IDENTIFIED AGENT. |
US10745439B2 (en) * | 2017-03-20 | 2020-08-18 | Regents Of The University Of Minnesota | Kinase substrates and methods of use thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3952097A (en) * | 1974-09-27 | 1976-04-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5643761A (en) * | 1993-10-27 | 1997-07-01 | The Trustees Of Columbia University In The City Of New York | Method for generating a subtracted cDNA library and uses of the generated library |
US5912236A (en) * | 1993-03-25 | 1999-06-15 | Baylor College Of Medicine | Broad-spectrum tumor suppressor genes gene products and methods for tumor suppressor gene therapy |
US6025127A (en) * | 1994-01-14 | 2000-02-15 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection in histologic tissue |
US6051376A (en) * | 1994-09-30 | 2000-04-18 | The Trustees Of Columbia University In The City Of New York | Uses of mda-6 |
US6207145B1 (en) * | 1997-05-09 | 2001-03-27 | Pharma Pacific Pty Ltd. | Therapeutic applications of high dose interferon |
US20020048763A1 (en) * | 2000-02-04 | 2002-04-25 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis |
US20040086500A1 (en) * | 2000-05-11 | 2004-05-06 | Georges Bahr | Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA892518B (en) | 1988-04-08 | 1989-12-27 | Intracel Corp | Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells |
EP0737750B1 (en) | 1989-03-21 | 2003-05-14 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
AU683839B2 (en) | 1992-05-13 | 1997-11-27 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy |
US5399466A (en) * | 1993-01-15 | 1995-03-21 | Eastman Kodak Company | [Method of processing] photographic elements having fogged grains and development inhibitors for interimage |
EP1650303B1 (en) | 1993-10-27 | 2008-05-28 | The Trustees of Columbia University of the City of New York | Method for generating a substracted cDNA library and uses of the generated library |
-
2000
- 2000-02-29 US US09/515,363 patent/US7229822B1/en not_active Expired - Fee Related
-
2001
- 2001-02-28 CA CA002401741A patent/CA2401741A1/en not_active Abandoned
- 2001-02-28 EP EP01920197A patent/EP1259530A4/en not_active Withdrawn
- 2001-02-28 AU AU2001247274A patent/AU2001247274A1/en not_active Abandoned
- 2001-02-28 WO PCT/US2001/006960 patent/WO2001064707A1/en not_active Application Discontinuation
- 2001-02-28 JP JP2001564200A patent/JP2003531581A/en active Pending
-
2002
- 2002-01-22 US US10/055,475 patent/US20030022855A1/en not_active Abandoned
- 2002-08-26 US US10/228,897 patent/US7220575B2/en not_active Expired - Fee Related
-
2005
- 2005-01-24 US US11/042,922 patent/US20050186211A1/en not_active Abandoned
-
2007
- 2007-05-22 US US11/805,429 patent/US20070259372A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3952097A (en) * | 1974-09-27 | 1976-04-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5912236A (en) * | 1993-03-25 | 1999-06-15 | Baylor College Of Medicine | Broad-spectrum tumor suppressor genes gene products and methods for tumor suppressor gene therapy |
US5643761A (en) * | 1993-10-27 | 1997-07-01 | The Trustees Of Columbia University In The City Of New York | Method for generating a subtracted cDNA library and uses of the generated library |
US6025127A (en) * | 1994-01-14 | 2000-02-15 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection in histologic tissue |
US6051376A (en) * | 1994-09-30 | 2000-04-18 | The Trustees Of Columbia University In The City Of New York | Uses of mda-6 |
US6207145B1 (en) * | 1997-05-09 | 2001-03-27 | Pharma Pacific Pty Ltd. | Therapeutic applications of high dose interferon |
US20020048763A1 (en) * | 2000-02-04 | 2002-04-25 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis |
US20040086500A1 (en) * | 2000-05-11 | 2004-05-06 | Georges Bahr | Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048976A3 (en) * | 2006-10-18 | 2008-11-20 | Us Gov Health & Human Serv | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors |
US20100099745A1 (en) * | 2006-10-18 | 2010-04-22 | Suryaprakash Sambhara | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors |
US20110165600A1 (en) * | 2008-09-01 | 2011-07-07 | Masataka Kuwana | Diagnosis method and diagnosis kit for dermatomyositis |
Also Published As
Publication number | Publication date |
---|---|
EP1259530A1 (en) | 2002-11-27 |
CA2401741A1 (en) | 2001-09-07 |
US20070259372A1 (en) | 2007-11-08 |
JP2003531581A (en) | 2003-10-28 |
AU2001247274A1 (en) | 2001-09-12 |
US20030022855A1 (en) | 2003-01-30 |
US20030092043A1 (en) | 2003-05-15 |
US7220575B2 (en) | 2007-05-22 |
US7229822B1 (en) | 2007-06-12 |
WO2001064707A1 (en) | 2001-09-07 |
EP1259530A4 (en) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050186211A1 (en) | Use of mda-5 as an antiviral and antiproliferative agent | |
Schwaller et al. | Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. | |
Kang et al. | mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties | |
Sangfelt et al. | Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines | |
US20070293453A1 (en) | Combinatorial Methods For Inducing Cancer Cell Death | |
US20060292157A1 (en) | MDA-7 protein variants having antiproliferative activity | |
JP2002515267A (en) | Compounds related to anti-apoptotic genes and gene products, screening methods and uses | |
Zhang et al. | Grouper TRADD mediates innate antiviral immune responses and apoptosis induced by Singapore grouper iridovirus (SGIV) infection | |
Zhang et al. | Fish RIP1 mediates innate antiviral immune responses induced by SGIV and RGNNV infection | |
US20060140959A1 (en) | Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof | |
US6894157B2 (en) | Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation | |
US7339026B2 (en) | mda-9 protein | |
US20080108067A1 (en) | Cloning of the retinoic acid inducible gene-1 promoter and uses thereof | |
US7449565B2 (en) | Chimeric tumor suppressor gene and protein | |
Milano Jr et al. | Effects of overexpression of Ran/TC4 on mammalian cellsin vitro | |
Tune et al. | Sustained expression of the novel EBV-induced zinc finger gene, ZNFEB, is critical for the transition of B lymphocyte activation to oncogenic growth transformation | |
US20080069800A1 (en) | System for High Production of Natural and Personalized Interferons | |
JP2008029293A (en) | Method for screening cancer remedy and cancer remedy | |
Yoshida et al. | SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. | |
Gaddy | Analysis of host gene products that contribute to the induction of apoptosis by oncolytic vesicular stomatitis virus | |
Zta | Critical Role of p53 in Histone Deacetylase | |
Williams et al. | Inhibition of Double-Stranded RNA-and | |
by Stat | IFN | |
AU2002331641A1 (en) | Combinatorial methods for inducing cancer cell death |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |